Substituted propenyl piperazine derivatives as novel inhibitors of histone deacetylase

ABSTRACT

This invention comprises the novel compounds of formula (I) wherein R 1 , R 2 , R 3 , R 4  and X have defined meanings, having histone deacetylase inhibiting enzymatic activity; their preparation, compositions containing them and their use as a medicine.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is the national stage of Application NoPCT/EP2005/053611, filed Jul. 25, 2005, which claims priority from EPOPatent Application No. 04077171.9, filed Jul. 28, 2004 and U.S. patentapplication Ser. No. 60/592,357 filed Jul. 29, 2004, the entiredisclosures of which are hereby incorporated in their entirely.

This invention concerns compounds having histone deacetylase (HDAC)inhibiting enzymatic activity. It further relates to processes for theirpreparation, to compositions comprising them, as well as their use, bothin vitro and in vivo, to inhibit HDAC and as a medicine, for instance asa medicine to inhibit proliferative conditions, such as cancer andpsoriasis.

Nuclear histones are known as integral and dynamic components of themachinery responsible for regulating gene transcription and otherDNA-templated processes such as replication, repair, recombination, andchromosome segregation. They are the subject of post-translationalmodifications including acetylation, phosphorylation, methylation,ubiquitination, and ADP-ribosylation.

Histone deacetylase(s), herein referred to as “HDACs”, are enzymes thatcatalyze the removal of the acetyl modification on lysine residues ofproteins, including the core nucleosomal histones H2A, H2B, H3 and H4.Together with histone acetyltransferase(s), herein referred to as“HATs”, HDACs regulate the level of acetylation of the histones. Thebalance of acetylation of nucleosomal histones plays an important rolein transcription of many genes. Hypoacetylation of histones isassociated with condensed chromatin structure resulting in therepression of gene transcription, whereas acetylated histones areassociated with a more open chromatin structure and activation oftranscription.

Eleven structurally related HDACs have been described and fall into twoclasses. Class I HDACs consist of HDAC 1, 2, 3, 8 and 11 whereas classII HDACs consist of HDAC 4, 5, 6, 7, 9 and 10. Members of a third classof HDACs are structurally unrelated to the class I and class II HDACs.Class I/II HDACs operate by zinc-dependent mechanisms, whereas class IIIHDACs are NAD-dependent.

In addition to histones, other proteins have also been the substrate foracetylation, in particular transcription factors such as p53, GATA-1 andE2F; nuclear receptors such as the glucocorticoid receptor, the thyroidreceptors, the estrogen receptors; and cell-cycle regulating proteinssuch as pRb. Acetylation of proteins has been linked with proteinstabilization, such as p53 stabilization, recruitment of cofactors andincreased DNA binding. p53 is a tumour suppressor that can induce cellcycle arrest or apoptosis in response to a variety of stress signals,such as DNA damage. The main target for p53-induced cell cycle arrestseems to be the p21 gene. Next to its activation by p53, p21 has beenidentified by virtue of its association with cyclin/cyclin-dependentkinase complexes resulting in cell cycle arrest at both G1 and G2phases, its up-regulation during senescence, and its interaction withthe proliferating cell nuclear antigen.

The study of inhibitors of HDACs indicates that they play an importantrole in cell cycle arrest, cellular differentiation, apoptosis andreversal of transformed phenotypes.

The inhibitor Trichostatin A (TSA), for example, causes cell cyclearrest at both G1 and G2 phases, reverts the transformed phenotype ofdifferent cell lines, and induces differentiation of Friend leukemiacells and others. TSA (and suberoylanilide hydroxamic acid SAHA) havebeen reported to inhibit cell growth, induce terminal differentiation,and prevent the formation of tumours in mice (Finnin et al., Nature,401: 188-193, 1999).

Trichostatin A has also been reported to be useful in the treatment offibrosis, e.g. liver fibrosis and liver chirrhosis. (Geerts et al.,European Patent Application EP 0 827 742, published 11 Mar., 1998).

The pharmacophore for HDAC inhibitors consists of a metal-bindingdomain, which interacts with the zinc-containing active site of HDACs, alinker domain, and a surface recognition domain or capping region, whichinteracts with residues on the rim of the active site.

Inhibitors of HDACs have also been reported to induce p21 geneexpression. The transcriptional activation of the p21 gene by theseinhibitors is promoted by chromatin remodelling, following acetylationof histones H3 and H4 in the p21 promotor region. This activation of p21occurs in a p53-independent fashion and thus HDAC inhibitors areoperative in cells with mutated p53 genes, a hallmark of numeroustumours.

In addition HDAC inhibitors can have indirect activities such asaugmentation of the host immune response and inhibition of tumorangiogenesis and thus can suppress the growth of primary tumors andimpede metastasis (Mai et al., Medicinal Research Reviews, 25: 261-309).

In view of the above, HDAC inhibitors can have great potential in thetreatment of cell proliferative diseases or conditions, includingtumours with mutated p53 genes.

-   Patent application EP1472216 published on Aug. 14, 2003 discloses    bicyclic hydroxamates as inhibitors of histone deacetylase.-   Patent applications EP1485099, EP1485348, EP1485353, EP1485354,    EP1485364, EP1485365, EP1485370, EP1485378published on 18 Sep.,    2003, amongst others, disclose substituted    piperazinylpyrimidinylhydroxamic acids as inhibitors of histone    deacetylase furthermore EP1485365 discloses R306465.-   Patent application EP1492534 published on 9 Oct., 2003, discloses    carbamic acid compounds comprising a piperazine linkage, as HDAC    inhibitors.-   Patent application EP1495002 published on 23 Oct., 2003, disclose    substituted piperazinyl phenyl benzamide compounds, as histone    deacetylase inhibitors.-   Patent application WO04/009536 published on 29 Jan., 2004, discloses    derivatives containing an alkyl linker between the aryl group and    the hydroxamate, as histone deacetylase inhibitors.-   Patent application EP1525199 published on 12 Feb., 2004, discloses    (hetero)arylalkenyl substituted bicyclic hydroxamates, as histone    deacetylase inhibitors.-   Patent application WO04/063146 published on 29 Jul. 2004, discloses    derivatives of N-hydroxy-benzamide derivatives with    anti-inflammatory and antitumour activity.-   Patent application WO04/063169 published on 29 Jul. 2004, discloses    substituted aryl hydroxamate derivatives as histone deacetylase    inhibitors.-   Patent application WO04/072047 published on 26 Aug. 2004, discloses    indoles, benzimidazoles and naphhimidazoles as histone deacetylase    inhibitors.-   Patent application WO04/082638 published on 30 Sep. 2004, discloses    hydroxamates linked to non-aromatic heterocyclic ring systems as    histone deacetylase inhibitors.-   Patent application WO04/092115 published on 28 Oct. 2004, discloses    hydroxamate derivatives as histone deacetylase inhibitors.-   Patent application WO05/028447 published on 31 Mar. 2005, discloses    benzimidazoles as histone deacetylase inhibitors.-   Patent applications WO05/030704 and WO05/030705 published on 7 Apr.    2005, discloses benzamides as histone deacetylase inhibitors.-   Patent application WO05/040101 published on 6 May 2005, disloses    acylurea connected and sulfonylurea connected hydroxamates as    histone deacetylase inhibitors.-   Patent application WO05/040161 also published on 6 May 2005,    discloses biaryl linked hydroxamates as histone deacetylase    inhibitors.

The compounds of the present invention differ from the prior art instructure, in their pharmacological activity and/or pharmacologicalpotency.

The problem to be solved is to provide histone deacetylase inhibitorswith high enzymatic and cellular activity that have increasedbioavailability and/or in vivo potency.

The novel compounds of the present invention solve the above-describedproblem. The compounds of the present invention show excellent histonedeacetylase inhibiting enzymatic and cellular activity. They have a highcapacity to activate the p21 gene, both at the cellular and the in vivolevel. They have a desirable pharmacokinetic profile and low affinityfor the P450 enzymes, which reduces the risk of adverse drug-druginteraction allowing also for a wider safety margin.

Advantageous features of the present compounds are metabolic stability,solubility and/or p21 induction capacity. More in particular thecompounds of the present invention have increased half-lives in rathepatocytes, have an increased solubility/stability in aqueous solutionsand/or have enhanced in vivo p21 promotor inducing capacities.

This invention concerns compounds of formula (I)

the N-oxide forms, the pharmaceutically acceptable addition salts andthe stereo-chemically isomeric forms thereof, wherein

-   each X is independently N or CH;-   R¹ is phenyl, naphtalenyl or heterocyclyl; wherein-   each of said phenyl or naphtalenyl is optionally substituted with    one or two substituents each independently selected from halo,    C₁₋₆alkyl, C₁₋₆alkyloxy, polyhaloC₁₋₆alkyl, aryl, hydroxy, cyano,    amino, C₁₋₆alkylcarbonylamino, C₁₋₆alkylsulfonylamino,    hydroxycarbonyl, C₁₋₆alkyloxycarbonyl, hydroxyC₁₋₆alkyl,    C₁₋₆alkyloxymethyl, aminomethyl, C₁₋₆alkylaminomethyl,    C₁₋₆alkylcarbonylaminomethyl, C₁₋₆alkylsulfonylaminomethyl,    aminosulfonyl, C₁₋₆alkylaminosulfonyl or heterocyclyl;-   R² is hydrogen, —CH₂—R⁵, trifluoromethyl, —C(═O)—R⁶, or —CH₂—NR⁷R⁸;    wherein-   each R⁵ is independently selected from hydrogen, hydroxy,    C₁₋₆alkyloxy, C₁₋₆alkyloxyC₁₋₆alkyloxy, C₁₋₆alkylcarbonyloxy,    piperazinyl, N-methylpiperazinyl, morpholinyl, thiomorpholinyl,    imidazolyl or triazolyl; each R⁶ is independently selected from    hydroxy, C₁₋₆alkyloxy, amino or mono- or di(C₁₋₆alkyl)amino,    C₁₋₆cycloalkylamino, hydroxyC₁₋₆alkylamino, piperazinyl, mono- or    di(C₁₋₆alkyl)aminoC₁₋₆alkylamino N-methylpiperazinyl, morpholinyl or    thiomorpholinyl; each R⁷ and R⁸ are independently selected from    hydrogen, C₁₋₆alkyl, C₁₋₆alkylcarbonyl, C₁₋₆alkylsulfonyl, or    mono-or di(C₁₋₄alkyl)aminosulfonyl;-   R³ is hydrogen, hydroxymethyl, aminomethyl or mono- or    di(C₁₋₆alkyl)aminomethyl;-   R⁴ is hydrogen or C₁₋₆alkyl;-   aryl in the above is phenyl or naphtalenyl; wherein-   each of said phenyl or naphtalenyl is optionally substituted with    one or two substituents each independently selected from halo,    C₁₋₆alkyl, C₁₋₆alkyloxy, trifluoromethyl, cyano or hydroxycarbonyl;    and-   heterocyclyl in the above is furanyl, thienyl, pyrrolyl, pyrrolinyl,    pyrolidinyl, dioxolyl, oxazolyl, thiazolyl, imidazolyl,    imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl,    isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl,    pyranyl, pyridinyl, piperidinyl, dioxanyl, morpholinyl, dithianyl,    thiomorpholinyl, pyridazinyl, pyrimidinyl, pyrazinyl, piperazinyl,    triazinyl, trithianyl, indolizinyl, indolyl, indolinyl,    benzofuranyl, benzothiophenyl, indazolyl, benzimidazolyl,    benzthiazolyl, purinyl, quinolizinyl, quinolinyl, cinnolinyl,    phthlazinyl, quinazolinyl, quinoxalinyl or naphthyridinyl; wherein-   each of said heterocycles is optionally substituted with one or two    substituents each independently selected from halo, C₁₋₆alkyl,    C₁₋₆alkyloxy, cyano, amino, mono-or di(C₁₋₄alkyl)amino.

The term “histone deacetylase inhibitor” or “inhibitor of histonedeacetylase” is used to identify a compound, which is capable ofinteracting with a histone deacetylase and inhibiting its activity, moreparticularly its enzymatic activity. Inhibiting histone deacetylaseenzymatic activity means reducing the ability of a histone deacetylaseto remove an acetyl group from a histone. Preferably, such inhibition isspecific, i.e. the histone deacetylase inhibitor reduces the ability ofa histone deacetylase to remove an acetyl group from a histone at aconcentration that is lower than the concentration of the inhibitor thatis required to produce some other, unrelated biological effect.

As used in the foregoing definitions and hereinafter, halo is generic tofluoro, chloro, bromo and iodo; C₁₋₄alkyl defines straight and branchedchain saturated hydrocarbon radicals having from 1 to 4 carbon atomssuch as, e.g. methyl, ethyl, propyl, butyl, 1-methylethyl,2-methylpropyl and the like; C₁₋₆alkyl includes C₁₋₄alkyl and the higherhomologues thereof having 5 to 6 carbon atoms such as, for example,pentyl, 2-methyl-butyl, hexyl, 2-methylpentyl and the like;polyhaloC₁₋₆alkyl defines C₁₋₆alkyl containing three identical ordifferent halo substituents for example trifluoromethyl; andC₃₋₆cycloalkyl includes cyclic hydrocarbon groups having from 3 to 6carbons, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl,cyclohexyl and the like.

Pharmaceutically acceptable addition salts encompass pharmaceuticallyacceptable acid addition salts and pharmaceutically acceptable baseaddition salts. The pharmaceutically acceptable acid addition salts asmentioned hereinabove are meant to comprise the therapeutically activenon-toxic acid addition salt forms, which the compounds of formula (I)are able to form. The compounds of formula (I) which have basicproperties can be converted in their pharmaceutically acceptable acidaddition salts by treating said base form with an appropriate acid.Appropriate acids comprise, for example, inorganic acids such ashydrohalic acids, e.g. hydrochloric or hydrobromic acid; sulfuric;nitric; phosphoric and the like acids; or organic acids such as, forexample, acetic, trifluoroacetic, propanoic, hydroxyacetic, lactic,pyruvic, oxalic, malonic, succinic (i.e. butanedioic acid), maleic,fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic,benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic,p-amino-salicylic, pamoic and the like acids.

The compounds of formula (I) which have acidic properties may beconverted in their pharmaceutically acceptable base addition salts bytreating said acid form with a suitable organic or inorganic base.Appropriate base salt forms comprise, for example, the ammonium salts,the alkali and earth alkaline metal salts, e.g. the lithium, sodium,potassium, magnesium, calcium salts and the like, salts with organicbases, e.g. the benzathine, N-methyl-D-glucamine, hydrabamine salts, andsalts with amino acids such as, for example, arginine, lysine and thelike.

The term “acid or base addition salts” also comprises the hydrates andthe solvent addition forms, which the compounds of formula (I) are ableto form. Examples of such forms are e.g. hydrates, alcoholates and thelike.

The term “stereochemically isomeric forms of compounds of formula (I)”,as used herein, defines all possible compounds made up of the same atomsbonded by the same sequence of bonds but having differentthree-dimensional structures, which are not interchangeable, which thecompounds of formula (I) may possess. Unless otherwise mentioned orindicated, the chemical designation of a compound encompasses themixture of all possible stereochemically isomeric forms, which saidcompound may possess. Said mixture may contain all diastereomers and/orenantiomers of the basic molecular structure of said compound. Allstereochemically isomeric forms of the compounds of formula (I) both inpure form or in admixture with each other are intended to be embracedwithin the scope of the present invention.

The N-oxide forms of the compounds of formula (I) are meant to comprisethose compounds of formula (I) wherein one or several nitrogen atoms areoxidized to the so-called N-oxide, particularly those N-oxides whereinone or more of the piperidine-, piperazine or pyridazinyl-nitrogens areN-oxidized.

Some of the compounds of formula (I) may also exist in their tautomericforms. Such forms although not explicitly indicated in the above formulaare intended to be included within the scope of the present invention.

Whenever used hereinafter, the term “compounds of formula (I)” is meantto include also the pharmaceutically acceptable addition salts and allstereoisomeric forms.

As used herein, the terms “histone deacetylase” and “HDAC” are intendedto refer to any one of a family of enzymes that remove acetyl groupsfrom the ε-amino groups of lysine residues at the N-terminus of ahistone. Unless otherwise indicated by context, the term “histone” ismeant to refer to any histone protein, including H1, H2A, H2B, H3, H4,and H5, from any species. Human HDAC proteins or gene products, include,but are not limited to, HDAC-1, HDAC-2, HDAC-3, HDAC-4, HDAC-5, HDAC-6,HDAC-7, HDAC-8, HDAC-9, HDAC-10 and HDAC-11. The histone deacetylase canalso be derived from a protozoal or fungal source.

A first group of interesting compounds consists of those compounds offormula (I) wherein one or more of the following restrictions apply:

-   a) R¹ is phenyl or naphtalenyl; wherein-    each said phenyl or naphtalenyl is substituted with one or two    substituents each independently selected from    C₁₋₆alkylsulfonylamino, hydroxycarbonyl, C₁₋₆alkyloxymethyl,    C₁₋₆alkylaminomethyl, C₁₋₆alkylcarbonylaminomethyl,    C₁₋₆alkylsulfonylaminomethyl, aminosulfonyl or    C₁₋₆alkylaminosulfonyl; or-   b) R² is —CH₂—R⁵, trifluoromethyl, —C(═O)—R⁶, or —CH₂—NR⁷R⁸;-   c) R⁴ is C₁₋₆alkyl.

A second group of interesting compounds consists of those compounds offormula (I) wherein one or more of the following restrictions apply:

-   a) R¹ is phenyl, naphtalenyl or heterocyclyl; wherein-    each said phenyl is substituted with one or two substituents each    independently selected from aryl, hydroxy, amino,    C₁₋₆alkylcarbonylamino, C₁₋₆alkylsulfonylamino,    C₁₋₆alkyloxycarbonyl, hydroxyC₁₋₆alkyl, C₁₋₆alkyloxymethyl,    aminomethyl, C₁₋₆alkylaninomethyl, C₁₋₆alkylcarbonylaaminomethyl,    C₁₋₆alkylsulfonylaminomethyl, aminosulfonyl, C₁₋₆alkylaminosulfonyl    or heterocyclyl; or-   b) R² is —CH₂—R⁵, trifluoromethyl, —C(═O)—R⁶, or —CH₂—NR⁷R⁸;-   c) R⁴ is C₁₋₆alkyl.

A third group of interesting compounds consists of those compounds offormula (I) wherein one or more of the following restrictions apply:

-   a) R¹ is phenyl, naphtalenyl or heterocyclyl; wherein-    each said phenyl or naphtalenyl is substituted with one or two    substituents each independently selected from    C₁₋₆alkylsulfonylamino, C₁₋₆alkyloxymethyl, aminomethyl,    C₁₋₆alkylaminomethyl, C₁₋₆alkylcarbonylaminomethyl,    C₁₋₆alkylsulfonylaminomethyl, aminosulfonyl, or    C₁₋₆alkylaminosulfonyl; or-   b) R² is —CH₂—R⁵, trifluoromethyl, —C(═O)—R⁶, or —CH₂—NR⁷R⁸;-   c) R⁴ is C₁₋₆alkyl.

A fourth group of interesting compounds consists of those compounds offormula (I) wherein one or more of the following restrictions apply:

-   a) each R⁵ is independently selected from hydrogen, hydroxy,    C₁₋₆alkyloxy, piperazinyl, N-methylpiperazinyl, morpholinyl,    thiomorpholinyl, imidazolyl or triazolyl;-   b) each R⁶ is independently selected from hydroxy, C₁₋₆alkyloxy,    amino or mono- or di(C₁₋₆alkyl)amino, C₁₋₆cycloalkylamino,    piperazinyl, N-methylpiperazinyl, morpholinyl or thiomorpholinyl;-   c) R⁴ is hydrogen.

A fifth group of interesting compounds consists of those compounds offormula (I) wherein one or more of the following restrictions apply:

-   a) each X is N;-   b) R¹ is phenyl or phenyl optionally substituted with halo,    C₁₋₆alkyl, C₁₋₆alkyloxy, polyhaloC₁₋₆alkyl or aryl;-   c) R² is —CH₂—R or —C(═O)—R⁶;-   d) each R⁵ is independently selected from hydrogen, hydroxy,    C₁₋₆alkyloxy, C₁₋₆alkyloxyC₁₋₆alkyloxy, C₁₋₆alkylcarbonyloxy,    N-methylpiperazinyl, morpholinyl, or imidazolyl;-   e) each R⁶ is independently selected from C₁₋₆alkylamino,    C₁₋₆cycloalkylamino, hydroxyC₁₋₆alkylamino,    di(C₁₋₆alkyl)aminoC₁₋₆alkylamino or morpholinyl;-   f) R³ is hydrogen; or-   g) R⁴ is hydrogen or C₁₋₆alkyl.

A sixth group of interesting compounds consists of those compounds ofthe fifth group wherein the following restriction apply:

-   a) each R⁶ is independently selected from C₁₋₆alkylamino,    C₁₋₆cycloalkylamino, di(C₁₋₆alkyl)aminoC₁₋₆alkylamino or    morpholinyl.

A seventh group of interesting compounds consists of those compounds offormula (I) wherein one or more of the following restrictions apply:

-   a) each X is N;-   b) R¹ is phenyl or phenyl substituted with halo;-   c) R² is —CH₂—R⁵;-   d) each R⁵ is independently selected from hydrogen, hydroxy,    C₁₋₆alkyloxy, or C₁₋₆alkylcarbonyloxy;-   e) R³ is hydrogen;-   f) R⁴ is hydrogen.

A group of preferred compounds consists of those compounds of formula(I) wherein each X is N; R¹ is phenyl or phenyl optionally substitutedwith halo, C₁₋₆alkyl, C₁₋₆alkyloxy, polyhaloC₁₋₆alkyl or aryl; R² is—CH₂—R⁵ or —C(═O)—R⁶; each R⁵ is independently selected from hydrogen,hydroxy, C₁₋₆alkyloxy, C₁₋₆alkyloxyC₁₋₆alkyloxy, C₁₋₆alkylcarbonyloxy,N-methylpiperazinyl, morpholinyl or imidazolyl; each R⁶ is independentlyselected from C₁₋₆alkylamino, C₁₋₆cycloalkylamino,hydroxyC₁₋₆alkylamino, di(C₁₋₆alkyl)aminoC₁₋₆alkylamino or morpholinyl;R³ is hydrogen and R⁴ is hydrogen or C₁₋₆alkyl.

Another group of preferred compounds consists of those compounds offormula (I) wherein R² is —CH₂—R⁵, trifluoromethyl, —C(═O)—R⁶, or—CH₂—NR⁷R⁸.

A group of more preferred compounds consists of those compounds offormula (I) wherein each X is N; R¹ is phenyl or phenyl substituted withhalo; R² is —CH₂—R⁵; each R⁵ is independently selected from hydrogen,hydroxy, C₁₋₆alkyloxy, or C₁₋₆alkylcarbonyloxy; R³ is hydrogen; and R⁴is hydrogen.

Most preferred compound is compound No. 1, compound No. 8, compound No.11, compound No. 9, compound No. 33, compound No. 34 and compound No. 7and compound No. 25.

Compound No. 1

Compound No. 8

Compound No. 11

Compound No. 9

Compound No. 33; •HCl; enantiomer A

Compound No. 34; •HCl; enantiomer B

Compound No. 7; C₂HF₃O₂; (E)

Compound No. 25; enantiomer A

The compounds of formula (I) and their pharmaceutically acceptable saltsand N-oxides and stereochemically isomeric forms thereof may be preparedin conventional manner. The starting materials and some of theintermediates are known compounds and are commercially available or maybe prepared according to conventional reaction procedures generallyknown in the art.

Some preparation methods will be described hereinafter in more detail.Other methods for obtaining final compounds of formula (I) are describedin the examples.

a) Hydroxamic acids of formula (I) may be prepared by reacting anintermediate of formula (II) with an appropriate acid, such as forexample, trifluoro acetic acid. Said reaction is performed in anappropriate solvent, such as, for example, methanol or dichloromethane.

b) Intermediates of formula (II) may be prepared by reacting anintermediate of formula (III) with an intermediate of formula (IV) inthe presence of appropriate reagents such asN′-(ethylcarbonimidoyl)-N,N-dimethyl-1,3-propanediamine,monohydrochloride (EDC) and 1-hydroxy-1H-benzotriazole (HOBT). Thereaction may be performed in the presence of a base such astriethylamine, in a suitable solvent, such as, a mixture ofdichloromethane and tetrahydrofuran.

c) In an alternative way the intermediates of formula (II), wherein R⁴is hydrogen, herein referred to as intermediates of formula (II-a) canbe prepared in a single step by reacting the intermediate of formula(XI), with 1,4-dioxane-2,5-diol and the appropriate boronic acid offormula (VII), wherein R¹ is as defined above, in a suitable solvent,e.g. an alcohol, such as ethanol.

d) Intermediates of formula (III) may be prepared by reacting anintermediate of formula (V) with an appropriate acidic solution, e.g.hydrochloric acid, or basic solution, e.g. hydrogen bromide orsodiumhydroxide, in a suitable solvent e.g. an alcohol, such as ethanolor propanol.

The present invention also concerns compounds of formula (V)

the N-oxide forms, the pharmaceutically acceptable addition salts andthe stereo-chemically isomeric forms thereof, wherein

-   each X is independently N or CH;-   R¹ is phenyl, naphtalenyl or heterocyclyl; wherein-   each of said phenyl or naphtalenyl is optionally substituted with    one or two substituents each independently selected from halo,    C₁₋₆alkyl, C₁₋₆alkyloxy, polyhaloC₁₋₆alkyl, aryl, hydroxy, cyano,    amino, C₁₋₆alkylcarbonylamino, C₁₋₆alkylsulfonylamino,    hydroxycarbonyl, C₁₋₆alkyloxycarbonyl, hydroxyC₁₋₆alkyl,    C₁₋₆alkyloxymethyl, aminomethyl, C₁₋₆alkylaminomethyl,    C₁₋₆alkylcarbonylaminomethyl, C₁₋₆alkylsulfonylaminomethyl,    aminosulfonyl, C₁₋₆alkylaminosulfonyl or heterocyclyl;-   R² is hydrogen, —CH₂—R⁵, trifluoromethyl, —C(═O)—R⁶, or —CH₂—NR⁷R⁸;    wherein-   each R⁵ is independently selected from hydrogen, hydroxy,    C₁₋₆alkyloxy, C₁₋₆alkyloxyC₁₋₆alkyloxy, C₁₋₆alkylcarbonyloxy,    piperazinyl, N-methylpiperazinyl, morpholinyl, thiomorpholinyl,    imidazolyl or triazolyl; each R⁶ is independently selected from    hydroxy, C₁₋₆alkyloxy, amino or mono- or di(C₁₋₆alkyl)amino,    C₁₋₆cycloalkylamino, hydroxyC₁₋₆alkylamino, piperazinyl, mono- or    di(C₁₋₆alkyl)aminoC₁₋₆alkylamino N-methylpiperazinyl, morpholinyl or    thiomorpholinyl; each R⁷ and R⁸ are independently selected from    hydrogen, C₁₋₆alkyl, C₁₋₆alkylcarbonyl, C₁₋₆alkylsulfonyl, or    mono-or di(C₁₋₄alkyl)aminosulfonyl;-   R³ is hydrogen, hydroxymethyl, aminomethyl or mono- or    di(C₁₋₆alkyl)aminomethyl;-   R⁴ is hydrogen or C₁₋₆alkyl;-   aryl in the above is phenyl or naphtalenyl; wherein-   each of said phenyl or naphtalenyl is optionally substituted with    one or two substituents each independently selected from halo,    C₁₋₆alkyl, C₁₋₆alkyloxy, trifluoromethyl, cyano or hydroxycarbonyl;    and-   heterocyclyl in the above is furanyl, thienyl, pyrrolyl, pyrrolinyl,    pyrolidinyl, dioxolyl, oxazolyl, thiazolyl, imidazolyl,    imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl,    isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl,    pyranyl, pyridinyl, piperidinyl, dioxanyl, morpholinyl, dithianyl,    thiomorpholinyl, pyridazinyl, pyrimidinyl, pyrazinyl, piperazinyl,    triazinyl, trithianyl, indolizinyl, indolyl, indolinyl,    benzofuranyl, benzothiophenyl, indazolyl, benzimidazolyl,    benzthiazolyl, purinyl, quinolizinyl, quinolinyl, cinnolinyl,    phthlazinyl, quinazolinyl, quinaxolinyl or naphthyridinyl; wherein-   each of said heterocycles is optionally substituted with one or two    substituents each independently selected from halo, C₁₋₆alkyl,    C₁₋₆alkyloxy, cyano, amino, or mono- or di(C₁₋₄alkyl)amino.

Groups of interesting, preferred, more preferred and most preferredcompounds can be defined for the compounds of formula (V), in accordancewith the groups defined for the compounds of formula (I).

The novel intermediates of formula (V) can be prepared by:

a) Converting intermediates of formula (V), wherein R² is —CH₂OH, and R⁴is hydrogen, herein referred to as intermediates of formula (V-a), intointermediates of formula (V) wherein R² is other than —CH₂OH, hereinreferred to as intermediates of formula (V-b), via art-known reactionsor functional group transformations. For example the alcohols of formula(V-a) can be converted into amines, esters and ethers. The amines can betransformed into the corresponding amides and the primary amines may beconverted into secondary or tertiary amines.

b) The novel intermediates of formula (V-a) can be prepared in a singlestep by reacting the intermediate of formula (VI), with1,4-dioxane-2,5-diol and the appropriate boronic acid of formula (VII),wherein R¹ is as defined above, in a suitable solvent, e.g. an alcohol,such as ethanol.

c) The novel intermediates of formula (V-b) can be prepared by reactingthe intermediates of formula (VI) with the appropriate ketone of formula(VIII) in the presence of an appropriate reagent, such astetrakis(ethanolato)titanium or a sodium borohydride, in a suitablesolvent e.g. 1,2-dichloroethane.

d) The novel intermediates of formula (V), wherein R² is —COOH hereinreferred to as compounds of formula (V-c) can be prepared in a singlestep by reacting the intermediate of formula (VI), with 2-oxo-propanoicacid and the appropriate boronic acid of formula (VII), wherein R¹ is asdefined above, in a suitable solvent, e.g. 1,2-dichloromethaneIntermediates of formula (V-c), wherein R² is —COOH, can be convertedinto intermediates of formula (V) wherein R is —C(═O)—R⁶, via art-knownreactions or functional group transformations, for example theconvertion into amines and amides.

The intermediates of formula (XI) may be prepared by reacting theintermediate of formula (IX) with piperidine in a suitable solvent e.g.dichloromethane.

The intermediates of formula (IX) may be prepared by reacting anintermediate of formula (X) with an intermediate of formula (IV), in thepresence of appropriate reagents such asN′-(ethylcarbonimidoyl)-N,N-dimethyl-1,3-propanediamine,monohydrochloride (EDC) and 1-hydroxy-1H-benzotriazole (HOBT). Thereaction may be performed in the presence of a base such astriethylamine, in a suitable solvent, such as, a mixture ofdichloromethane and tetrahydrofuran.

Intermediates of formula (X) may be prepared by reacting an intermediateof formula (VI) with an intermediate of formula (XII), in the presenceof sodium hydroxide, in a suitable solvent, such as tetrahydrofuran,followed by neutralization with hydrochloric acid and addition of sodiumcarbonate.

The compounds of formula (I) and some of the intermediates may have atleast one stereogenic centre in their structure. This stereogenic centremay be present in an R or an S configuration.

The compounds of formula (I) as prepared in the hereinabove describedprocesses are generally racemic mixtures of enantiomers, which can beseparated from one another following art-known resolution procedures.The racemic compounds of formula (I) may be converted into thecorresponding diastereomeric salt forms by reaction with a suitablechiral acid. Said diastereomeric salt forms are subsequently separated,for example, by selective or fractional crystallization and theenantiomers are liberated there from by alkali. An alternative manner ofseparating the enantiomeric forms of the compounds of formula (I)involves liquid chromatography using a chiral stationary phase. Saidpure stereochemically isomeric forms may also be derived from thecorresponding pure stereochemically isomeric forms of the appropriatestarting materials, provided that the reaction occursstereospecifically. Preferably if a specific stereoisomer is desired,said compound would be synthesized by stereospecific methods ofpreparation. These methods will advantageously employ enantiomericallypure starting materials.

The compounds of formula (I), the pharmaceutically acceptable acidaddition salts and stereoisomeric forms thereof have valuablepharmacological properties in that they have a histone deacetylase(HDAC) inhibitory effect.

This invention provides a method for inhibiting the abnormal growth ofcells, including transformed cells, by administering an effective amountof a compound of the invention. Abnormal growth of cells refers to cellgrowth independent of normal regulatory mechanisms (e.g. loss of contactinhibition). This includes the inhibition of tumour growth both directlyby causing growth arrest, terminal differentiation and/or apoptosis ofcancer cells, and indirectly, by inhibiting neovascularization oftumours.

This invention also provides a method for inhibiting tumour growth byadministering an effective amount of a compound of the presentinvention, to a subject, e.g. a mammal (and more particularly a human)in need of such treatment. In particular, this invention provides amethod for inhibiting the growth of tumours by the administration of aneffective amount of the compounds of the present invention. Examples oftumours which may be inhibited, but are not limited to, lung cancer(e.g. adenocarcinoma and including non-small cell lung cancer),pancreatic cancers (e.g. pancreatic carcinoma such as, for exampleexocrine pancreatic carcinoma), colon cancers (e.g. colorectalcarcinomas, such as, for example, colon adenocarcinoma and colonadenoma), prostate cancer including the advanced disease, hematopoietictumours of lymphoid lineage (e.g. acute lymphocytic leukemia, B-celllymphoma, Burkitt's lymphoma), myeloid leukemias (for example, acutemyelogenous leukemia (AML)), thyroid follicular cancer, myelodysplasticsyndrome (MDS), tumours of mesenchymal origin (e.g. fibrosarcomas andrhabdomyosarcomas), melanomas, teratocarcinomas, neuroblastomas,gliomas, benign tumour of the skin (e.g. keratoacanthomas), breastcarcinoma (e.g. advanced breast cancer), kidney carcinoma, ovarycarcinoma, bladder carcinoma and epidermal carcinoma.

The compound according to the invention may be used for othertherapeutic purposes, for example:

-   -   a) the sensitisation of tumours to radiotherapy by administering        the compound according to the invention before, during or after        irradiation of the tumour for treating cancer;    -   b) treating arthropathies and osteopathological conditions such        as rheumatoid arthritis, osteoarthritis, juvenile arthritis,        gout, polyarthritis, psoriatic arthritis, ankylosing spondylitis        and systemic lupus erythematosus;    -   c) inhibiting smooth muscle cell proliferation including        vascular proliferative disorders, atherosclerosis and        restenosis;    -   d) treating inflammatory conditions and dermal conditions such        as ulcerative colitis, Crohn's disease, allergic rhinitis, graft        vs. host disease, conjunctivitis, asthma, ARDS, Behcets disease,        transplant rejection, uticaria, allergic dermatitis, alopecia        areata, scleroderma, exanthema, eczema, dermatomyositis, acne,        diabetes, systemic lupus erythematosis, Kawasaki's disease,        multiple sclerosis, emphysema, cystic fibrosis and chronic        bronchitis;    -   e) treating endometriosis, uterine fibroids, dysfunctional        uterine bleeding and endometrial hyperplasia;    -   f) treating ocular vascularisation including vasculopathy        affecting retinal and choroidal vessels;    -   g) treating a cardiac dysfunction;    -   h) inhibiting immunosuppressive conditions such as the treatment        of HIV infections;    -   i) treating renal dysfunction;    -   j) suppressing endocrine disorders;    -   k) inhibiting dysfunction of gluconeogenesis;    -   l) treating a neuropathology for example Parkinson's disease or        a neuropathology that results in a cognitive disorder, for        example, Alzheimer's disease or polyglutamine related neuronal        diseases;    -   m) treating psychiatric disorders for example schizophrenia,        bipolar disorder, depression, anxiety and psychosis;    -   n) inhibiting a neuromuscular pathology, for example,        amylotrophic lateral sclerosis;    -   o) treating spinal muscular atrophy;    -   p) treating other pathologic conditions amenable to treatment by        potentiating expression of a gene;    -   q) enhancing gene therapy;    -   r) inhibiting adipogenesis;    -   s) treating parasitosis such as malaria.

Hence, the present invention discloses the compounds of formula (I) foruse as a medicine as well as the use of these compounds of formula (I)for the manufacture of a medicament for treating one or more of theabove mentioned conditions.

The compounds of formula (I), the pharmaceutically acceptable acidaddition salts and stereoisomeric forms thereof can have valuablediagnostic properties in that they can be used for detecting oridentifying a HDAC in a biological sample comprising detecting ormeasuring the formation of a complex between a labelled compound and aHDAC.

The detecting or identifying methods can use compounds that are labelledwith labelling agents such as radioisotopes, enzymes, fluorescentsubstances, luminous substances, etc. Examples of the radioisotopesinclude ¹²⁵I, ¹³¹I, ³H and ¹⁴C. Enzymes are usually made detectable byconjugation of an appropriate substrate which, in turn catalyses adetectable reaction. Examples thereof include, for example,beta-galactosidase, beta-glucosidase, alkaline phosphatase, peroxidaseand malate dehydrogenase, preferably horseradish peroxidase. Theluminous substances include, for example, luminol, luminol derivatives,luciferin, aequorin and luciferase.

Biological samples can be defined as body tissue or body fluids.Examples of body fluids are cerebrospinal fluid, blood, plasma, serum,urine, sputum, saliva and the like.

In view of their useful pharmacological properties, the subjectcompounds may be formulated into various pharmaceutical forms foradministration purposes.

To prepare the pharmaceutical compositions of this invention, aneffective amount of a particular compound, in base or acid addition saltform, as the active ingredient is combined in intimate admixture with apharmaceutically acceptable carrier, which carrier may take a widevariety of forms depending on the form of preparation desired foradministration. These pharmaceutical compositions are desirably inunitary dosage form suitable, preferably, for administration orally,rectally, percutaneously, or by parenteral injection. For example, inpreparing the compositions in oral dosage form, any of the usualpharmaceutical media may be employed, such as, for example, water,glycols, oils, alcohols and the like in the case of oral liquidpreparations such as suspensions, syrups, elixirs and solutions; orsolid carriers such as starches, sugars, kaolin, lubricants, binders,disintegrating agents and the like in the case of powders, pills,capsules and tablets.

Because of their ease in administration, tablets and capsules representthe most advantageous oral dosage unit form, in which case solidpharmaceutical carriers are obviously employed. For parenteralcompositions, the carrier will usually comprise sterile water, at leastin large part, though other ingredients, to aid solubility for example,may be included. Injectable solutions, for example, may be prepared inwhich the carrier comprises saline solution, glucose solution or amixture of saline and glucose solution. Injectable suspensions may alsobe prepared in which case appropriate liquid carriers, suspending agentsand the like may be employed. In the compositions suitable forpercutaneous administration, the carrier optionally comprises apenetration enhancing agent and/or a suitable wetting agent, optionallycombined with suitable additives of any nature in minor proportions,which additives do not cause a significant deleterious effect to theskin. Said additives may facilitate the administration to the skinand/or may be helpful for preparing the desired compositions. Thesecompositions may be administered in various ways, e.g., as a transdermalpatch, as a spot-on or as an ointment.

It is especially advantageous to formulate the aforementionedpharmaceutical compositions in dosage unit form for ease ofadministration and uniformity of dosage. Dosage unit form as used in thespecification and claims herein refers to physically discrete unitssuitable as unitary dosages, each unit containing a predeterminedquantity of active ingredient, calculated to produce the desiredtherapeutic effect, in association with the required pharmaceuticalcarrier. Examples of such dosage unit forms are tablets (includingscored or coated tablets), capsules, pills, powder packets, wafers,injectable solutions or suspensions, teaspoonfuls, tablespoonfuls andthe like, and segregated multiples thereof.

Those skilled in the art could easily determine the effective amountfrom the test results presented hereinafter. In general it iscontemplated that a therapeutically effective amount would be from 0.005mg/kg to 100 mg/kg body weight, and in particular from 0.005 mg/kg to 10mg/kg body weight. It may be appropriate to administer the required doseas two, three, four or more sub-doses at appropriate intervalsthroughout the day. Said sub-doses may be formulated as unit dosageforms, for example, containing 0.5 to 500 mg, and in particular 10 mg to500 mg of active ingredient per unit dosage form.

As another aspect of the present invention a combination of aHDAC-inhibitor with another anticancer agent is envisaged, especiallyfor use as a medicine, more specifically in the treatment of cancer orrelated diseases.

For the treatment of the above conditions, the compounds of theinvention may be advantageously employed in combination with one or moreother medicinal agents, more particularly, with other anti-canceragents. Examples of anti-cancer agents are:

-   -   platinum coordination compounds for example cisplatin,        carboplatin or oxalyplatin;    -   taxane compounds for example paclitaxel or docetaxel;    -   topoisomerase I inhibitors such as camptothecin compounds for        example irinotecan or topotecan;    -   topoisomerase II inhibitors such as anti-tumour podophyllotoxin        derivatives for example etoposide or teniposide;    -   anti-tumour vinca alkaloids for example vinblastine, vincristine        or vinorelbine;    -   anti-tumour nucleoside derivatives for example 5-fluorouracil,        gemcitabine or capecitabine;    -   alkylating agents such as nitrogen mustard or nitrosourea for        example cyclophosphamide, chlorambucil, carmustine or lomustine;    -   anti-tumour anthracycline derivatives for example daunorubicin,        doxorubicin, idarubicin or mitoxantrone;    -   HER2 antibodies for example trastuzumab;    -   estrogen receptor antagonists or selective estrogen receptor        modulators for example tamoxifen, toremifene, droloxifene,        faslodex or raloxifene;    -   aromatase inhibitors such as exemestane, anastrozole, letrazole        and vorozole;    -   differentiating agents such as retinoids, vitamin D and retinoic        acid metabolism blocking agents (RAMBA) for example accutane;    -   DNA methyl transferase inhibitors for example azacytidine;    -   kinase inhibitors for example flavoperidol, imatinib mesylate or        gefitinib;    -   farnesyltransferase inhibitors;    -   other HDAC inhibitors    -   inhibitors of the ubiquitin-proteasome pathway for example        Velcade; or    -   Yondelis.

The term “platinum coordination compound” is used herein to denote anytumour cell growth inhibiting platinum coordination compound whichprovides platinum in the form of an ion.

The term “taxane compounds” indicates a class of compounds having thetaxane ring system and related to or derived from extracts from certainspecies of yew (Taxus) trees.

The term “topisomerase inhibitors” is used to indicate enzymes that arecapable of altering DNA topology in eukaryotic cells. They are criticalfor important cellular functions and cell proliferation. There are twoclasses of topoisomerases in eukaryotic cells, namely type I and typeII. Topoisomerase I is a monomeric enzyme of approximately 100,000molecular weight. The enzyme binds to DNA and introduces a transientsingle-strand break, unwinds the double helix (or allows it to unwind)and subsequently reseals the break before dissociating from the DNAstrand. Topisomerase II has a similar mechanism of action which involvesthe induction of DNA strand breaks or the formation of free radicals.

The term “camptothecin compounds” is used to indicate compounds that arerelated to or derived from the parent camptothecin compound which is awater-insoluble alkaloid derived from the Chinese tree Camptothecinacuminata and the Indian tree Nothapodytes foetida.

The term “podophyllotoxin compounds” is used to indicate compounds thatare related to or derived from the parent podophyllotoxin, which isextracted from the mandrake plant.

The term “anti-tumour vinca alkaloids” is used to indicate compoundsthat are related to or derived from extracts of the periwinkle plant(Vinca rosea).

The term “alkylating agents” encompass a diverse group of chemicals thathave the common feature that they have the capacity to contribute, underphysiological conditions, alkyl groups to biologically vitalmacromolecules such as DNA. With most of the more important agents suchas the nitrogen mustards and the nitrosoureas, the active alkylatingmoieties are generated in vivo after complex degradative reactions, someof which are enzymatic. The most important pharmacological actions ofthe alkylating agents are those that disturb the fundamental mechanismsconcerned with cell proliferation in particular DNA synthesis and celldivision. The capacity of alkylating agents to interfere with DNAfunction and integrity in rapidly proliferating tissues provides thebasis for their therapeutic applications and for many of their toxicproperties.

The term “anti-tumour anthracycline derivatives” comprise antibioticsobtained from the fungus Strep. peuticus var. caesius and theirderivatives, characterised by having a tetracycline ring structure withan unusual sugar, daunosamine, attached by a glycosidic linkage.

Amplification of the human epidermal growth factor receptor 2 protein(HER 2) in primary breast carcinomas has been shown to correlate with apoor clinical prognosis for certain patients. Trastuzumab is a highlypurified recombinant DNA-derived humanized monoclonal IgG1 kappaantibody that binds with high affinity and specificity to theextracellular domain of the HER2 receptor.

Many breast cancers have estrogen receptors and growth of these tumourscan be stimulated by estrogen. The terms “estrogen receptor antagonists”and “selective estrogen receptor modulators” are used to indicatecompetitive inhibitors of estradiol binding to the estrogen receptor(ER). Selective estrogen receptor modulators, when bound to the ER,induces a change in the three-dimensional shape of the receptor,modulating its binding to the estrogen responsive element (ERE) on DNA.

In postmenopausal women, the principal source of circulating estrogen isfrom conversion of adrenal and ovarian androgens (androstenedione andtestosterone) to estrogens (estrone and estradiol) by the aromataseenzyme in peripheral tissues. Estrogen deprivation through aromataseinhibition or inactivation is an effective and selective treatment forsome postmenopausal patients with hormone-dependent breast cancer.

The term “antiestrogen agent” is used herein to include not onlyestrogen receptor antagonists and selective estrogen receptor modulatorsbut also aromatase inhibitors as discussed above.

The term “differentiating agents” encompass compounds that can, invarious ways, inhibit cell proliferation and induce differentiation.Vitamin D and retinoids are known to play a major role in regulatinggrowth and differentiation of a wide variety of normal and malignantcell types. Retinoic acid metabolism blocking agents (RAMBA's) increasethe levels of endogenous retinoic acids by inhibiting the cytochromeP450-mediated catabolism of retinoic acids.

DNA methylation changes are among the most common abnormalities in humanneoplasia. Hypermethylation within the promotors of selected genes isusually associated with inactivation of the involved genes. The term“DNA methyl transferase inhibitors” is used to indicate compounds thatact through pharmacological inhibition of DNA methyl transferase andreactivation of tumour suppressor gene expression.

The term “kinase inhibitors” comprises potent inhibitors of kinases thatare involved in cell cycle progression and programmed cell death(apoptosis)

The term “famesyltransferase inhibitors” is used to indicate compoundsthat were designed to prevent farnesylation of Ras and otherintracellular proteins. They have been shown to have effect on malignantcell proliferation and survival.

The term “other HDAC inhibitors” comprises but is not limited to:

-   -   carboxylates for example butyrate, cinnamic acid,        4-phenylbutyrate or valproic acid;    -   hydroxamic acids for example suberoylanilide hydroxamic acid        (SAHA), piperazine containing SAHA analogues, biaryl hydroxamate        A-161906 and its carbozolylether-, tetrahydropyridine- and        tetralone-analogues, bicyclic aryl-N-hydroxycarboxamides,        pyroxamide, CG-1521, PXD-101, sulfonamide hydroxamic acid,        LAQ-824, LBH-589, trichostatin A (TSA), oxamflatin, scriptaid,        scriptaid related tricyclic molecules, m-carboxy cinnamic acid        bishydroxamic acid (CBHA), CBHA-like hydroxarnic acids,        trapoxin-hydroxamic acid analogue, R306465 and related benzoyl-        and heteroaryl-hydroxamic acids, aminosuberates and        malonyldiamides;    -   cyclic tetrapeptides for example trapoxin, apidicin,        depsipeptide, spiruchostatin-related compounds, RedFK-228,        sulfhydryl-containing cyclic tetrapeptides (SCOPs), hydroxamic        acid containing cyclic tetrapeptides (CHAPs), TAN-174s and        azumamides;    -   benzamides for example MS-275 or CI-994, or    -   depudecin.

The term “inhibitors of the ubiquitin-proteasome pathway” is used toindentify compounds that inhibit the targeted destruction of cellularproteins in the proteasome, including cell cycle regulatory proteins.

For the treatment of cancer the compounds according to the presentinvention may be administered to a patient as described above, inconjunction with irradiation. Irradiation means ionising radiation andin particular gamma radiation, especially that emitted by linearaccelerators or by radionuclides that are in common use today. Theirradiation of the tumour by radionuclides can be external or internal.

The present invention also relates to a combination according to theinvention of an anti-cancer agent and a HDAC inhibitor according to theinvention.

The present invention also relates to a combination according to theinvention for use in medical therapy for example for inhibiting thegrowth of tumour cells.

The present invention also relates to a combinations according to theinvention for inhibiting the growth of tumour cells.

The present invention also relates to a method of inhibiting the growthof tumour cells in a human subject which comprises administering to thesubject an effective amount of a combination according to the invention.

This invention further provides a method for inhibiting the abnormalgrowth of cells, including transformed cells, by administering aneffective amount of a combination according to the invention.

The other medicinal agent and HDAC inhibitor may be administeredsimultaneously (e.g. in separate or unitary compositions) orsequentially in either order. In the latter case, the two compounds willbe administered within a period and in an amount and manner that issufficient to ensure that an advantageous or synergistic effect isachieved. It will be appreciated that the preferred method and order ofadministration and the respective dosage amounts and regimes for eachcomponent of the combination will depend on the particular othermedicinal agent and HDAC inhibitor being administered, their route ofadministration, the particular tumour being treated and the particularhost being treated. The optimum method and order of administration andthe dosage amounts and regime can be readily determined by those skilledin the art using conventional methods and in view of the information setout herein.

The platinum coordination compound is advantageously administered in adosage of 1 to 500 mg per square meter (mg/m²) of body surface area, forexample 50 to 400 mg/m², particularly for cisplatin in a dosage of about75 mg/m² and for carboplatin in about 300 mg/m² per course of treatment.

The taxane compound is advantageously administered in a dosage of 50 to400 mg per square meter (mg/m²) of body surface area, for example 75 to250 mg/m², particularly for paclitaxel in a dosage of about 175 to 250mg/m² and for docetaxel in about 75 to 150 mg/m² per course oftreatment.

The camptothecin compound is advantageously administered in a dosage of0.1 to 400 mg per square meter (mg/m²) of body surface area, for example1 to 300 mg/m², particularly for irinotecan in a dosage of about 100 to350 mg/m² and for topotecan in about 1 to 2 mg/m² per course oftreatment.

The anti-tumour podophyllotoxin derivative is advantageouslyadministered in a dosage of 30 to 300 mg per square meter (mg/m²) ofbody surface area, for example 50 to 250 mg/m², particularly foretoposide in a dosage of about 35 to 100 mg/m² and for teniposide inabout 50 to 250 mg/m² per course of treatment.

The anti-tumour vinca alkaloid is advantageously administered in adosage of 2 to 30 mg per square meter (mg/m²) of body surface area,particularly for vinblastine in a dosage of about 3 to 12 mg/m², forvincristine in a dosage of about 1 to 2 mg/M², and for vinorelbine indosage of about 10 to 30 mg/m² per course of treatment.

The anti-tumour nucleoside derivative is advantageously administered ina dosage of 200 to 2500 mg per square meter (mg/m²) of body surfacearea, for example 700 to1500 mg/m², particularly for 5-FU in a dosage of200 to 500 mg/m², for gemcitabine in a dosage of about 800 to 1200 mg/m²and for capecitabine in about 1000 to 2500 mg/m² per course oftreatment.

The alkylating agents such as nitrogen mustard or nitrosourea isadvantageously administered in a dosage of 100 to 500 mg per squaremeter (mg/m²) of body surface area, for example 120 to 200 mg/m²,particularly for cyclophosphamide in a dosage of about 100 to 500 mg/m²,for chlorambucil in a dosage of about 0.1 to 0.2 mg/kg, for carmustinein a dosage of about 150 to 200 mg/m², and for lomustine in a dosage ofabout 100 to 150 mg/m² per course of treatment.

The anti-tumour anthracycline derivative is advantageously administeredin a dosage of 10 to 75 mg per square meter (mg/m²) of body surfacearea, for example 15 to 60 mg/m², particularly for doxorubicin in adosage of about 40 to 75 mg/m², for daunorubicin in a dosage of about 25to 45 mg/m² , and for idarubicin in a dosage of about 10 to 15 mg/m² percourse of treatment.

Trastuzumab is advantageously administered in a dosage of 1 to 5 mg persquare meter (mg/m²) of body surface area, particularly 2 to 4 mg/m² percourse of treatment.

The antiestrogen agent is advantageously administered in a dosage ofabout 1 to 100 mg daily depending on the particular agent and thecondition being treated. Tamoxifen is advantageously administered orallyin a dosage of 5 to 50 mg, preferably 10 to 20 mg twice a day,continuing the therapy for sufficient time to achieve and maintain atherapeutic effect. Toremifene is advantageously administered orally ina dosage of about 60 mg once a day, continuing the therapy forsufficient time to achieve and maintain a therapeutic effect.Anastrozole is advantageously administered orally in a dosage of about 1mg once a day. Droloxifene is advantageously administered orally in adosage of about 20-100 mg once a day. Raloxifene is advantageouslyadministered orally in a dosage of about 60 mg once a day. Exemestane isadvantageously administered orally in a dosage of about 25 mg once aday.

These dosages may be administered for example once, twice or more percourse of treatment, which may be repeated for example every 7, 14, 21or 28 days.

In view of their useful pharmacological properties, the components ofthe combinations according to the invention, i.e. the other medicinalagent and the HDAC inhibitor may be formulated into variouspharmaceutical forms for administration purposes. The components may beformulated separately in individual pharmaceutical compositions or in aunitary pharmaceutical composition containing both components.

The present invention therefore also relates to a pharmaceuticalcomposition comprising the other medicinal agent and the HDAC inhibitortogether with one or more pharmaceutical carriers.

The present invention also relates to a combination according to theinvention in the form of a pharmaceutical composition comprising ananti-cancer agent and a HDAC inhibitor according to the inventiontogether with one or more pharmaceutical carriers.

The present invention further relates to the use of a combinationaccording to the invention in the manufacture of a pharmaceuticalcomposition for inhibiting the growth of tumour cells.

The present invention further relates to a product containing as firstactive ingredient a IDAC inhibitor according to the invention and assecond active ingredient an anticancer agent, as a combined preparationfor simultaneous, separate or sequential use in the treatment ofpatients suffering from cancer.

Experimental Part

The following examples are provided for purposes of illustration.Hereinafter, “EDC” is defined asN′-(ethylcarbonimidoyl)-N,N-dimethyl-1,3-propanediamine,monohydrochloride, “DCM” is defined as dichloromethane, “DIPE” isdefined as diisopropyl ether, “DMF” is defined as N,N-dimethylformamide,“EtOAc” is defined as ethyl acetate, “EtOH” is defined as ethanol,“HOBT” is defined as 1-hydroxy-1H-benzotriazole, “MeOH” is defined asmethanol, “TFA” is defined as trifluoroacetic acid and “THF” is definedas tetrahydrofuran.

A. Preparation of the Intermediate Compounds

EXAMPLE A1

a) Preparation of Intermediate 1

A mixture of 2-(1-piperazinyl)-5-pyrimidinecarboxylic acid, ethyl ester(0.016 mol), (2-phenylethenyl)-boronic acid (0.016 mol) and1,4-dioxane-2,5-diol (0.016 mol) in EtOH (250 ml) was stirred for 2 daysat room temperature and then the solvent was evaporated (vac.), Theresidue was taken up in DCM and water and the organic layer wasseparated, dried (MgSO₄), filtered and the solvent was evaporated. Theresidue was purified by column chromatography over silica gel (15-40 μm)(eluent: DCMIMeOH 97/1). The pure fractions were evaporated, yielding 4g (61%) of intermediate 1, melting point 128° C.

Esters, corresponding to intermediate 1, can be separated by chiralchromatography.

b) Prpapation of Intermediate 2

A mixture of intermediate 1 (0.0007 mol) in sodium hydroxide 1N (10 ml)and THF (20 ml) was stirred at room temperature for 48 hours.Hydrochloric acid 1N (10 ml) was added. The solvent was evaporated. Theprecipitate was filtered, washed with water, then with DIPE and dried,yielding 0.2 g (72%) of intermediate 2, melting point 232° C.

c) Preparation of Intermediate 3

Triethyl amine (0.012 mol),N′-(ethylcarbonimidoyl)-N,N-dimethyl-1,3-propanediamine (0.00593 mol),1-hydroxy-1H-benzotriazole (0.00593 mol) andO-(tetrahydro-2H-pyran-2-yl)-hydroxylamine (0.00593 mol) were added to amixture of intermediate 2 (0.00395 mol) in a mixture of DCM (70 ml) andTHF (70 ml), then the reaction mixture was stirred for 3 days at roomtemperature.H₂O was added. The organic layer was separated, dried(MgSO₄), filtered off and the solvent was evaporated. The residue waspurified by column chromatography (gradient eluent: DCM/MeOH/NHOH97/3/0.1). The product fractions were collected and the organic solventwas evaporated yielding 1.5 g (84%) of intermediate 3.

EXAMPLE A2

a) Preparation of Intermediate 4

A mixture of 2-(1-piperazinyl)-5-pyrimidinecarboxylic acid, ethyl ester(0.0042 mol), 1,4-dioxane-2,5-diol (0.0042 mol) and (E)[2-(4-chlorophenyl)ethenyl]-boronic acid (0.0042 mol) in EtOH (100 ml)was stirred at room temperature for 72 hours, poured out into water andextracted with DCM. The organic layer was separated, dried (MgSO₄),filtered, and the solvent was evaporated. The residue (1.8 g) waspurified by column chromatography over silica gel (15-40 μm) (eluent:DCM/MeOH/NH₄OH 97/3/0.1;). Two fractions were collected and the solventwas evaporated, yielding 0.85 g F1 (oil) and 0.25 g F2 (global yield:63%). F1 was crystallized from 2-propanone/DIPE. The precipitate wasfiltered off and dried, yielding 0.6 g of intermediate 4, melting point110° C.

b) Prepartion of Intermediate 5

Methanesulfonyl chloride (0.0012 mol) was added at 5° C. to a solutionof intermediate 4 (0.0006 mol) and triethyl amine (0.0024 mol) in THF(15 ml) under N₂ flow. The mixture was brought to room temperature, thenstirred for 1 hour and poured out into 15 ice water. The mixture wasextracted with DCM. The organic layer was separated, dried (MgSO₄),filtered, and the solvent was evaporated, yielding 0.3 g of intermediate5. This product was used directly in the next reaction step.

c) Preparation of Intermediate 6

A mixture of intermediate 5 (0.0006 mol), morpholine (0.0009 mol) andpotassium carbonate (0.0018 mol) in acetonitrile (30 ml) was stirred at80° C. for 15 hours, poured out into water and extracted with DCM. Theorganic layer was separated, dried (MgSO₄), filtered, and the solventwas evaporated. The residue (0.27 g) was purified by columnchromatography over silica gel (5 μm) (eluent: DCM/MeOH 100/0 to 90/10).The pure fractions were collected and the solvent was evaporated,yielding 0.085 g (29%) of intermediate 6.

d) Prepartion of Intermediate 7

A mixture of intermediate 6 (0.0002 mol) in sodium hydroxide 1N (1.5 ml)and THF (3 ml) was stirred at room temperature for 72 hours.Hydrochloric acid 1N (1.5 ml) was added. The mixture was evaporated tilldryness, yielding intermediate 7. This product was used directly in thenext reaction step.

e) Preparation of Intermediate 8

A mixture of intermediate 7 (0.0002 mol),O-(tetrahydro-2H-pyran-2-yl)-hydroxylamine (0.0002 mol), EDC (0.0002mol), HOBT (0.0002 mol) and triethyl amine (0.0002 mol) in DCM/THF (10ml) was stirred at room temperature for 48 hours, poured out into waterand extracted with EtOAc. The organic layer was separated, dried(MgSO₄), filtered, and the solvent was evaporated. The residue (0.095 g)was purified by column chromatography over silica gel (5 μm) (eluent:DCM/MeOH/NH₄OH 97/3/0.1). The pure fractions were collected and thesolvent was evaporated, yielding 0.04 g (41%) of intermediate 8.

EXAMPLE A3

a) Preparation of Intermediate 11

Titanium ethylate (0.0085 mol) was added at room temperature to asolution of 2-(1-piperazinyl)-5-pyrimidinecarboxylic acid, ethyl ester(0.0042 mol) and 4-phenyl-3-buten-2-one (0.0051 mol) in1,2-dichloro-ethane (45 ml) under N₂ flow. The mixture was stirred atroom temperature for 24 hours. NaBH(OAc)₃ (0.0085 mol) was added. Themixture was stirred for 5 hours and poured out into ice water. DCM wasadded. The mixture was filtered over celite. The organic layer wasseparated, dried (MgSO₄), filtered, and the solvent was evaporated. Theresidue (1.16 g) was purified by column chromatography over kromasil (5μm) (eluent: DCM/MeOH 100/0 to 95/5). The pure fractions were collectedand the solvent was evaporated, yielding 0.12 g (8%) of intermediate 11.

b) Preparation of Intermediate 12

A mixture of intermediate 11 (0.0003 mol) and sodium hydroxide (0.0013mol) in EtOH (15 ml) was stirred and refluxed for 3 hours, then cooledto room temperature and evaporated till dryness. The residue was takenup in diethyl ether. The precipitate was filtered off and dried,yielding 0.12 g (100%) of intermediate 12, melting point >260° C.

c.) Preparation of Intermediate 13

EDC (0.0006 mol) and HOBT (0.0006 mol) were added at room temperature toa solution of intermediate 12 (0.0003 mol) in THF (15 ml) and DCM (15 m)under N₂ flow. The mixture was stirred for 15 minutes.O-(tetrahydro-2H-pyran-2-yl)-hydroxylamine (0.0006 mol) was added. Themixture was stirred at room temperature for 48 hours, poured out intoice water and extracted with DCM. The organic layer was separated, dried(MgSO₄), filtered, and the solvent was evaporated. The residue (0.25 g)was purified by column chromatography over kromasil (5 μm) (eluent:DCM/MeOH 100/0 to 95/5). The pure fractions were collected and thesolvent was evaporated, yielding 0.1 g (70%) of intermediate 13.

EXAMPLE A4

a) Preparation of Intermediate 14

A mixture of 2-(1-piperazinyl)-5-pyrimidinecarboxylic acid, ethyl ester(0.059 mol) in THF (300 ml) and sodium hydroxide 1N (300 ml) was left tostand overnight at room temperature and then stirred. Hydrochloric acid1N (300 ml) was added and the mixture was stirred for 10 min. Sodiumcarbonate (0.178 mol) was added and the resulting mixture was stirredfor 10 minutes at room temperature, then1-[[(9H-fluoren-9-ylmethoxy)carbonyl]oxy]-2,5-pyrrolidinedione (0.059mol) was added in small portions and the reaction mixture was stirred atroom temperature for 15 hours. The mixture was acidified withconcentrated HCl and the precipitate was filtered off and dried (vac.),yielding 22.5 g (90%) of intermediate 14, melting point 218.5-221.2° C.

b) Preparation of Intermediate 15

Triethylamine (0.069 mol), then EDC (0.0303 mol) and HOBT (0.0303 mol)followed by O-(tetrahydro-2H-pyran-2-yl)-hydroxylamine (0.0303 mol) wereadded to a mixture of intermediate 14 (0.0233 mol) in DCM/THF (500 ml)and the reaction mixture was stirred at room temperature for 18 hours.The mixture was diluted with DCM and washed with water. The organiclayer was separated and washed with a 10% sodium carbonate solution. Theseparated organic layer was dried (MgSO₄), filtered off and the solventwas evaporated. The residue was purified by Flash column chromatography(eluent: DCM/MeOH 100/0 −>97.5/2.5 in 100 min.). The product fractionswere collected and the solvent was evaporated, yielding 8.4 g (68%) ofintermediate 15.

c) Preparation of Intermediate 16

A mixture of intermediate 15 (0.016 mol) in pyridine (0.040 mol) and DCM(200 ml) was stirred overnight at room temperature and the reactionmixture was extracted with water, then the aqueous layer wasconcentrated and co-evaporated with acetonitrile. The residue (3.5 g)was purified by Flash column chromatography (eluent: DCM/MeOH/NH₃)95/5/0.5). The product fractions were collected and the solvent wasevaporated, yielding 2.5 g (50%) of intermediate 16, melting point70.8-93.9 ° C.

d) Preparation of Intermediate 17

A mixture of intermediate 16 (0.002 mol), (E)[2-(4-fluorophenyl)ethenyl]-boronic acid (0.002 mol) and1,4-dioxane-2,5-diol (0.002 mol) in EtOH (25 ml) was stirred at roomtemperature for 15 hours, poured out on ice. NaHCO₃ was added. Themixture was extracted with DCM. The organic layer was separated, dried(MgSO₄), filtered, and the solvent was evaporated. The residue (0.68 g)was purified by column chromatography over kromasil (5 μm) (eluent:DCM/MeOH 100/0 to 90/10). The pure fractions were collected and thesolvent was evaporated, yielding 0.27 g (29%) of intermediate 17,melting point 90° C.

EXAMPLE A5

a) Preparation of Intermediate 18

2-Oxo-propanoic acid (0.0169 mol) then2-(1-piperazinyl)-5-pyrimidinecarboxylic acid, ethyl ester (0.0169 mol)were added to a solution of [2-(4-fluorophenyl)ethenyl]-boronic acid(0.0169 mol) in DCM (150 ml). The mixture was stirred at roomtemperature for 15 hours. 2-Oxo-propanoic acid (0.4 eq) and[2-(4-fluorophenyl)ethenyl]-boronic acid (0.1 eq) were added. Themixture was stirred at room temperature for 15 hours. The organic layerwas washed with water, dried (MgSO₄), filtered and the solvent wasevaporated. The residue (7.7 g) was purified by column chromatographyover silica gel (15-40 μm) (eluent: DCM/MeOH/NH₄OH 92/8/0.1). The purefractions were collected and the solvent was evaporated. This residue (6g) was dissolved in HCl 3N. The mixture was stirred at room temperaturefor 2 hours. The precipitate was filtered, washed with water (theminimum) and dried, yielding 2.8 g (36%) of intermediate 18.

b) Preparation of Intermediate 19

HOBT (0.0022 mol) then EDC (0.0022 mol) were added to a solution ofintermediate 18 (0.0015 mol), N-methyl-methanamine (0.0022 mol) andtriethylamine (0.0075 mol) in DCMITHF (40 ml). The mixture was stirredat room temperature for 24 hours, poured out into water and extractedwith DCM. The organic layer was separated, dried (MgSO₄), filtered andthe solvent was evaporated. The residue was taken up in DIPE. Theprecipitate was filtered off and dried, yielding 0.58 g (85%) ofintermediate 19, melting point 195° C.

c) Preparation of Intermediate 20

A mixture of intermediate 19 (0.0011 mol) and lithiumhydroxide (0.0023mol) in THF (20 ml) and water (10 ml) was stirred at room temperaturefor 15 hours. HCl 3N was added. THF was evaporated. The precipitate wasfiltered, washed with water, then with diethyl ether and dried, yielding0.45 g (82%) of intermediate 20.

d) Preparation of Intermediate 21

HOBT (0.0014 mol) then EDC (0.0014 mol) were added at room temperatureto a solution of intermediate 20 (0.0009 mol),O-(tetrahydro-2H-pyran-2-yl)-hydroxylamine (0.0014 mol) andtriethylamine (0.0043 mol) in DCM/THF (50/50) (75 ml). The mixture wasstirred at room temperature for 48 hours, poured out into water andextracted with DCM. The organic layer was separated, dried (MgSO),filtered and the solvent was evaporated. The residue (0.7 g) waspurified by column chromatography over silica gel (5 μm)(eluent:DCM/MeOH/NH₄OH 99/1/0.1 to 94/6/0.6). The pure fractions were collectedand the solvent was evaporated, yielding 0.38 g (75%) of intermediate21.

EXAMPLE A6

a) Preparation of Intermediate 22

Sodium hydride 60% (0.0085 mol) was added portionwise at 5° C. to asolution of intermediate 1 (0.0065 mol) in THF (60 ml) under N₂ flow.The mixture was stirred at 5° C. for 15 minutes. A solution ofiodomethane (0.0078 mol) in TEF (5 ml) was added dropwise. The mixturewas stirred at 5° C. for 1 hour, then stirred at room temperature for 5hours, poured out on ice and extracted with EtOAc. The organic layer wasseparated, dried (MgSO₄), filtered and the solvent was evaporated. Theresidue (1.75)g was purified by column chromatography over silica gel(15-40 μm) (eluent: DCM/MeOH 99/1). The pure fractions were collectedand the solvent was evaporated, yielding 0.87 g (34%) of intermediate22.

b) Pregparation of Intermediate 23

A mixture of intermediate 22 (0.0027 mol) and lithiumhydroxidemonohydrate (0.0055 mol) in THF (40 ml) and water (20 ml) was stirred atroom temperature for 48 hours, acidified with HCl 1N. THF wasevaporated. The precipitate was filtered, washed with a minimum of waterand dried, yielding: 0.91 g (83%) of intermediate 23.

c) Preparation of Intermediate 24

HOBT (0.0033 mol) then EDC (0.0033 mol) were added at room temperatureto a solution of intermediate 23 (0.0022 mol),O-(tetrahydro-2H-pyran-2-yl)-hydroxylamine (0.0033 mol) andtriethylamine (0.01 mol) in DCM/THF (90 ml) under N₂ flow. The mixturewas stirred at room temperature for 48 hours, poured out into water andextracted with DCM. The organic layer was separated, dried (MgSO₄),filtered and the solvent was evaporated. The residue (1.3 g) waspurified by column chromatography over silica gel (15-40 μm) (eluent:DCM/MeOH/NH4OH 97/3/0.1). The pure fractions were collected and thesolvent was evaporated, yielding 0.93 g (89%) of intermediate 24.

EXAMPLE A7

a) Preparation of Intermediate 25

A mixture of 2-(1-piperazinyl)-5-pyridylcarboxylic acid, ethyl ester(0.0085 mol), 1,4-dioxane-2,5-diol (0.0093 mol) and(E)-[2-(4-fluorophenyl)ethenyl]-boronic acid (0.0042 mol) in EtOH (200ml) was stirred at room temperature for 15 hours, then filtered. Thefiltrate was evaporated. The residue was taken up in EtOAc. The organiclayer was washed with saturated NaCl, dried (MgSO₄), filtered, and thesolvent was evaporated. The residue (3.3 g) was dissolved in diethylether and acidified by dropwise addition at 5° C. of HCl 5-6N inisopropanol (2 ml). The precipitate was filtered, washed with diethylether and dried. This fraction was taken up in water, K2CO3 was addedand the mixture was extracted by DCM. The organic layer was separated,dried (MgSO₄), filtered, and the solvent was evaporated, yielding 2.7 g(79%) of intermediate 25.

b) Preparation of Intermediate 26

A mixture of intermediate 25 ((0.002 mol), Lithium hydroxide (0.004 mol)in water (20 ml) and TIHF (40 ml) was stirred at room temperature for 15hours. The mixture was concentrated. Hydrochloric acid 3N was added. Theprecipitate was filtered, washed with water, then with diethyl ether anddried, yielding 0.52 g (63%) of intermediate 26.

c) Preparation of Intermediate 27

Triethyl amine (0.0057 mol),N′-(ethylcarbonimidoyl)-N,N-dimethyl-1,3-propanediamine (0.0019 mol),1-hydroxy-1H-benzotriazole (0.0019 mol) andO-(tetrahydro-2H-pyran-2-yl)-hydroxylamine (0.0019 mol) were added to amixture of intermediate 26 (0.0012 mol) in a mixture of DCM (50 ml) andTHF (50 ml). The reaction mixture was stirred for 24 h at roomtemperature, then poured out into H₂O and extracted by DCM. The organiclayer was separated, dried (MgSO₄), filtered off and the solvent wasevaporated. The residue was purified by column chromatography oversilica gel (gradient eluent: DCM/MeOH/NH₄OH 95/5/0.2). The productfractions were collected and the organic solvent was evaporated yielding0.55 g (91%). This residue was taken up in diethyl ether, theprecipitate was filtered off and dried yielding 0.5 g of intermediate27, melting point 133° C.

EXAMPLE A8

Preparation of Intermediate 28 and 29

Acetic anhydride (0.014 mol) was added dropwise at 5° C., to a mixtureof intermediate 3 (0.0014 mol), 4-N-N-dimethylaminopyridine (0.0095 g)and pyridine (2.5 ml) in DCM (14 ml). The mixture was stirred at roomtemperature for 24 h, concentrated, taken up in water and extracted withethylacetate. The organic layer was dried (MgSO₄), filtered off and thesolvent was evaporated. The residue was purified by columnchromatography over silica gel (5 μm)(gradient eluent: DCM/MeOH 95/5).The pure fractions were collected and the organic solvent was evaporatedyielding 0.48 g (58%) of intermediate 28. The oxalate salt was preparedon a fraction (0.05 g) and was crystallized from 2-propanone/dethylether. The precipitate was filtered off and dried, yielding 0.042 g ofintermediate 29, melting point 154° C.

Table F-1 lists the intermediates that were prepared according to one ofthe above Examples.

TABLE F-1 (intermediates)

Interm. 1; Ex. [A1]; mp. 128° C.

Interm. 9; Ex. [A1]

Interm. 4; Ex. [A1]; mp. 110.4° C.

(E); interm. 10; Ex. [A1]; mp. 139° C.

Interm. 11; Ex. [A3]

Interm. 19; Ex. [A5]; mp. 195° C.

Interm. 30; Ex. [A5]

Interm. 31; Ex. [A5]; mp. 196° C.

Interm. 32; Ex. [A5]; mp. 221° C.

Interm. 33; Ex. [A5]

Interm. 34; Ex. [A5]

Interm. 35; Ex. [A5]

Interm. 36; Ex. [A5]; mp. 144° C.

Interm. 37; Ex. [A5]

Interm. 38; Ex. [A2]

Interm. 39; Ex. [A2]

Interm. 40; Ex. [A2]

Interm. 22; Ex. [A6]

Co. No. 41; Ex. [A6]

Interm. 42; Ex. [A1] (enantiomer A)

Interm. 43; Ex. [A1]; mp. 146° C. (enantiomer B)

Interm. 44; Ex. [A1]; mp. 167° C. (enantiomer A)

Interm. 45; Ex. [A1] (enantiomer B)

Interm. 25; Ex. [A7]

Interm. 46; Ex. [A6]B. Preparation of the Final Compounds

EXAMPLE B1

Preparation of Compound 1

A mixture of intermediate 3 (0.00121 mol) in TFA (2.5 ml) and MeOH (50ml) was stirred for 48 hours and then the solvent was evaporated. Theresidue was purified by column chromatography over silica gelLiChroprep® NH₂ (25-40 μm) (eluent: DCM/MeOH/H₂O 80/20/2). The purefractions were collected and the solvent was evaporated. The residue wastaken up in diethylether and the precipitate was then filtered and dried(vac.) at 50° C., yielding 0.26 g (64%) of compound 1, melting point187° C.

EXAMPLE B2

Preparation of Compound 2

A mixture of intermediate 8 (0.00007 mol) in trifluoroacetic acid (0.2ml) and MeOH (4.5 ml) was stirred at room temperature for 96 hours. Thesolvent was evaporated till dryness. The residue was crystallized fromdiethyl ether/2-propanone. The precipitate was filtered off and dried,yielding 0.025 g (57%) of compound 2, melting point 135° C.

EXAMPLE B3

Preparation of Compound 7

A mixture of intermediate 13 (0.0002 mol) in TFA (0.5 ml) and MeOH (10ml) was stirred at room temperature for 48 hours, then evaporated tilldryness. The residue was crystallized from diethyl ether. Theprecipitate was filtered off and dried, yielding 0.044 g (44%) ofcompound 7, melting point 161° C.

EXAMPLE B4

Preparation of Compound 8

A mixture of intermediate 17 (0.0005 mol) in TFA (1.2 ml) and MeOH (24ml) was stirred at room temperature for 5 days. The solvent wasevaporated till dryness. The residue (0.26 g) was purified by columnchromatography over silica gel LiChroprep® NH2 (25-40 μm) (eluent:DCM/MeOH/H₂O 70/30/3). The pure fractions were collected and the solventwas evaporated. The residue (0.16 g) was crystallized from diethylether. The precipitate was filtered off and dried, yielding 0.13 g (66%)of compound 8, melting point 180° C.

EXAMPLE B5

Preparation of Compound 9

A mixture of intermediate 28 (0.0004 mol) in TFA (1 ml) and MeOH (20 ml)was stirred at room temperature for 96 hours, then evaporated. Theresidue (0.23 g) was purified by column chromatography over silica gelLiChroprep® NH₂ (25-40 μm) (eluent: DCM/MeOH/H₂O 80/20/2). The purefractions were collected and the solvent was evaporated. The residue(0.106 g) was crystallized from diethyl ether/DIPE. The precipitate wasfiltered off and dried, yielding 0.067 g (34%) of compound 9, meltingpoint 161° C.

EXAMPLE B6

Preparation of Compound 10

TFA (1.9 ml) was added dropwise at 5° C. to a solution of intermediate21 (0.0007 mol) in MeOH (38 ml). The mixture was stirred at roomtemperature for 48 hours then evaporated till dryness. The residue wascrystallized from diethyl ether/CH₃CN. The precipitate was filtered,washed with diethyl ether and dried, yielding 0.24 g (62%) of compound10, melting point 146° C.

EXAMPLE B7

Preparation of Compound 11

A mixture of intermediate 24 (0.0018 mol) in TFA (4.4 ml) and MeOH (87ml) was stirred at room temperature for 4 days, then evaporated tilldryness. The residue (1.05 g) was purified by column chromatography oversilica gel LiChroprep® NH₂ (25-40 μm) (eluent: DCM/MeOH/H₂O 80/20/2).The pure fractions were collected and the solvent was evaporated. Thisfraction (0.634 g) was taken up in diethyl ether. The precipitate wasfiltered off and dried, yielding 0.43 g of compound 11, melting point212° C.

EXAMPLE B8

Preparation of Compound 31

A mixture of intermediate 27 (0.0011 mol) in trifluoroacetic acid (3 ml)and MeOH (60 ml) was stirred at room temperature for 48 hours. Thesolvent was evaporated till dryness. The residue was crystallized fromdiethyl ether. The precipitate was filtered off and dried, yielding0.515 g (89%) of compound 31, melting point 145° C.

Table F-2 lists the compounds that were prepared according to one of theabove Examples. The following abbreviations were used in the tables:.C₂HF₃O₂ stands for the trifluoroacetate salt.

TABLE F-2 (final compounds)

Co. No. 1; Ex. [B1]; mp. 187° C.

C₂HF₃O₂•H₂O; Co. No. 2; Ex. [B2]; mp. 135° C.

(E).C₂HF₃O₂•H₂O; Co. No. 3; Ex. [B1]; mp. 160° C.

(E).C₂HF₃O₂; Co. No. 4; Ex. [B1]; mp. 156° C.

C₂HF₃O₂•H₂O; Co. No. 5; Ex. [B1]; mp. 185° C.

C₂HF₃O₂•H₂O; Co. No. 6; Ex. [B1]; mp. 160° C.

C₂HF₃O₂; (E); Co. No. 7; Ex. [B3]; mp. 161° C.

Co. No. 8; Ex. [B4]; mp. 180° C.

Co. No. 9; Ex. [B5]; mp. 161° C.

•C₂HF₃O₂•H₂O; Co. No. 10; Ex. [B6]; mp. 146° C.

Co. No. 11; Ex. [B7]; mp. 212° C.

•C₂HF₃O₂•H₂O (E); Co. No. 12; Ex. [B4]; mp. 128° C.

Co. No. 13; Ex. [B6]; mp. 130° C.

•C₂HF₃O₂•H₂O; Co. No. 14; Ex. [B6]; mp. 134° C.

•C₂HF₃O₂•H₂O; Co. No. 15; Ex. [B6]; mp. 159° C.

•C₂HF₃O₂; Co. No. 16; Ex. [B6]; mp. 131° C.

Co. No. 17; Ex. [B6]; mp. 209° C.

Co. No. 18; Ex. [B6]; mp. 130° C.

•C₂HF₃O₂•H₂O; Co. No. 19; Ex. [B6]; mp. 130° C.

•C₂HF₃O₂; Co. No. 20; Ex. [B6]; mp. 128° C.

Co. No. 21; Ex. [B2]; mp. 110° C.

(E); Co. No. 22; Ex. [B2]; mp. 115° C.

•C₂HF₃O₂•H₂O; Co. No. 23; Ex. [B2]; mp. 106° C.

Co. No. 24; Ex. [B7]; mp. 170° C.

Co. No. 25; Ex. [B1]; mp. 203° C.; enantiomer A

Co. No. 26; Ex. [B1]; mp. 207° C.; enantiomer B

Co. No. 27; Ex. [B1]; mp. 218° C.; enantiomer A

Co. No. 28; Ex. [B1]; mp. 214° C.; enantiomer B

Co. No. 29; Ex. [B1]; mp. 166° C.

Co. No. 30; Ex. [B1]; mp. 190° C.

Co. No. 31; Ex. [B8]; mp. 145° C.

Co. No. 32; Ex. [B7]; mp. 217° C.

•HCl; Co. No. 33; Ex. [B1]; mp. 256° C.; enantiomer A

•HCl; Co. No. 34; Ex. [B1]; mp. 254° C.; enantiomer B

(E); Co. No. 35; Ex. [B3]; mp. 202° C.C. Pharmacological Example:

The in vitro assay for inhibition of histone deacetylase (see exampleC.1) measures the inhibition of HDAC enzymatic activity obtained withthe compounds of formula (I).

Cellular activity of the compounds of formula (I) was determined onA2780 tumour cells using a calorimetric assay for cell toxicity orsurvival (Mosmann Tim, Journal of Immunological Methods 65: 55-63,1983)(see example C.2).

The solubility of a compound measures the ability of a compound to stayin solution. In a first method the ability of a compound to stay inaqueous solution upon dilution (see example C.3.a) is measured.DMSO-stock solutions are diluted with a single aqueous buffer solvent in3 consecutive steps. For every dilution turbidity is measured with anephelometer.

In a second method the solubility of a compound at different pH's can bemeasured with the use of a chemiluminescent nitrogen detector (seeexample C.3.b).

A drug's permeability expresses its ability to move from one medium intoor through another. Specifically its ability to move through theintestinal membrane into the blood stream and/or from the blood streaminto the target. Permeability (see example C.4) can be measured throughthe formation of a filter-immobilized artificial membrane phospholipidbilayer. In the filter-immobilized artificial membrane assay, a“sandwich” is formed with a 96-well microtitre plate and a 96-wellfilter plate, such that each composite well is divided into two chamberswith a donor solution at the bottom and an acceptor solution at the top,separated by a 125 μm micro-filter disc (0.45 μm pores), coated with2%(wt/v) dodecane solution of dioleoylphosphatidyl-choline, underconditions that multi-lamellar bilayers form inside the filter channelswhen the system contacts an aqueous buffer solution. The permeability ofcompounds through this artificial membrane is measured in crn/s. Thepurpose is to look for the permeation of the drugs through a parallelartificial membrane at 2 different pH's: 4.0 and 7.4. Compound detectionis done with UV-spectrometry at optimal wavelength between 250 and 500nm.

Metabolism of drugs means that a lipid-soluble xenobiotic or endobioticcompound is enzymatically transformed into (a) polar, water-soluble, andexcretable metabolite(s). The major organ for drug metabolism is theliver. The metabolic products are often less active than the parent drugor inactive. However, some metabolites may have enhanced activity ortoxic effects. Thus drug metabolism may include both “detoxication” and“toxication” processes. One of the major enzyme systems that determinethe organism's capability of dealing with drugs and chemicals isrepresented by the cytochrome P450 monooxygenases, which are NADPHdependent enzymes. Metabolic stability of compounds can be determined invitro with the use of subcellular human tissue (see example C.5.a.).Here metabolic stability of the compounds is expressed as % of drugmetabolised after 15 minutes incubation of these compounds withmicrosomes. Quantitation of the compounds was determined by LC-MSanalysis. Metabolic stability of compounds can also be determined bycalculating the half live of compounds in rat hepatocyte cells (seeexample C.5.b.).

It has been shown that a wide variety of anti-tumoral agents activatethe p21 protein, including DNA damaging agents and histone deacetylaseinhibitors. DNA damaging agents activate the p21 gene through the tumoursuppressor p53, while histone deacetylase inhibitors transcriptionallyactivates the p21 gene via the transcription factor Sp1. Thus, DNAdamaging agents activate the p21 promoter through the p53 responsiveelement while histone deacetylase inhibitors activate the p21 promoterthrough sp1 sites (located at the −60 bp to +40 bp region relative tothe TATA box) both leading to increased expression of the p21 protein.When the p21 promoter in a cells consists of a p21 1300 bp promoterfragment that does not comprise the p53 responsive elements it isaccordingly non-responsive to DNA damaging agents. The capacity ofcompounds to induce p21 can be evaluated in several ways. A first methodis to treat tumour cells with the compound of interest and after lysisof the cells detects p21 induction with the p21 enzyme linkedimmunosorbent assay (WAF1 ELISA of Oncogene). The p21 assay is a“sandwich” enzyme immunoassay employing both mouse monoclonal and rabbitpolyclonal antibodies. A rabbit polyclonal antibody, specific for thehuman p21 protein, has been immobilized onto the surface of the plasticwells provided in the kit. Any p21 present in the sample to be assayedwill bind to the capture antibody. The biotinylated detector monoclonalantibody also recognizes human p21 protein, and will bind to any p21,which has been retained by the capture antibody. The detector antibody,in turn, is bound by horseradish peroxidas-conjugated streptavidin. Thehorseradish peroxidase catalyses the conversion of the chromogenicsubstrate tetra-methylbenzidine from a colorless solution to a bluesolution (or yellow after the addition of stopping reagent), theintensity of which is proportional to the amount of p21 protein bound tothe plate. The colored reaction product is quantified using aspectrophotometer. Quantitation is achieved by the construction of astandard curve using known concentrations of p21 (provided lyophilised).This assay can measures p21 induction as the consequence of DNA damageor as the consequence of histone deacetylase inhibition (see exampleC.6.a.).

Another method tests the capacity of compounds to induce p21 as theconsequence of HDAC inhibition at the cellular level. The cells can bestably transfected with an expression vector containing a p21 1300bppromoter fragment that does not comprise the p53 responsive elements andwherein an increase of a reporter gene expression, compared to thecontrol levels, identifies the compound as having p21 inductioncapacity. The reporter gene is a fluorescent protein and the expressionof the reporter gene is measured as the amount of fluorescent lightemitted (see example C.6.b.). The last method is an in vivo methodwherein mice are used for screening the pharmaceutical activity of acompound. The above described stably transformed tumour cells can beadministered to mice in an amount sufficient to effect production of atumour. After the tumour cells had sufficient time to form a tumour, apotentially active compound can be administered to the animals and theeffect of said compound on the tumour cells is evaluated by measuringthe expression of the reporter gene. Incubation with pharmaceuticalactive compounds will result in an increase of reporter gene expressioncompared to the control levels (see example C.6.c.)

Specific HDAC inhibitors should not inhibit other enzymes like theabundant CYP P450 proteins. The CYP P450 (E.coli expressed) proteins3A4, 2D6 en 2C9 convert their specific substrates into a fluorescentmolecule. The CYP3A4 protein converts 7-benzyloxy-trifluoromethylcoumarin (BFC) into 7-hydroxy-trifluoromethyl coumarin. The CYP2D6protein converts3-[2-(N,N-diethyl-N-methylamino)ethyl]-7-methoxy-4-methylcoumarin (AMMC)into 3-[2-(N,N-diethylamino)ethyl]-7-hydroxy-4-methylcoumarinhydrochloride and the CYP2C9 protein converts7-Methoxy-4-trifluoromethyl coumarin (MFC) into7-hydroxy-trifluoromethyl coumarin. Compounds inhibiting the enzymaticreaction will result in a decrease of fluoresent signal (see exampleC.7).

EXAMPLE C.1 In Vitro Assay for Inhibition of Histone Deacetylase:

The HDAC Fluorescent Activity Assay/Drug Discovery Kit of Biomol(cat.No: AK-500-0001) was used. The HDAC Fluorescent Activity Assay isbased on the Fluor de Lys (Fluorogenic Uistone deAcetylase Lysyl)substrate and developer combination. The Fluor de Lys substrate,comprises an acetylated lysine side chain. Deacetylation of thesubstrate sensitizes the substrate so that, in the second step,treatment with the Fluor de Lys developer produces a fluorophore.

HeLa nuclear extracts (supplier: Biomol) were incubated at 60 μg/ml with75 μM of substrate. The Fluor de Lys substrate was added in a buffercontaining 25 mM Tris, 137 mM NaCl, 2.7 mM KCl and 1 mM MgCl₂.6H₂O at pH7.4. After 30 min, 1 volume of the developer was added. The fluorophorewas excited with 355 nm light and the emitted light (450 nm) was bedetected on a fluorometric plate reader. For each experiment, controls(containing HeLa nuclear extract and buffer), a blank incubation(containing buffer but no HeLa nuclear extract) and samples (containingcompound dissolved in DMSO and further diluted in buffer and HeLanuclear extract) were run in parallel. In first instance, compounds weretested at a concentration of 10⁻⁵ M. When the compounds showed activityat 10⁻⁵M, a concentration-response curve was made wherein the compoundswere tested at concentrations between 10⁻⁵M and 10⁻⁹M. All sample weretested 4 times. In each test the blank value was substracted from boththe control and the sample values. The control sample represented 100%of substrate deactylation. For each sample the fluorescence wasexpressed as a percentage of the mean value of the controls. Whenappropriate IC₅₀-values (concentration of the drug, needed to reduce theamount of metabolites to 50% of the control) were computed using probitanalysis for graded data. Herein the effects of test compounds areexpressed as pIC₅₀ (the negative log value of the IC₅₀-value) (see TableF-3).

EXAMPLE C.2 Determination of Antiproliferative Activity on A2780 Cells

All compounds tested were dissolved in DMSO and further dilutions weremade in culture medium. Final DMSO concentrations never exceeded 0.1%(v/v) in cell proliferation assays. Controls contained A2780 cells andDMSO without compound and blanks contained DMSO but no cells. MTT wasdissolved at 5 mg/ml in PBS. A glycine buffer comprised of 0.1 M glycineand 0.1 M NaCl buffered to pH 10.5 with NaOH (1 N) was prepared (allreagents were from Merck).

The human A2780 ovarian carcinoma cells (a kind gift from Dr. T. C.Hamilton [Fox Chase Cancer Centre, Pennsylvania, USA]) were cultured inRPMI 1640 medium supplemented with 2 mM L-glutamine, 50 μg/ml gentamicinand 10% fetal calf serum.

Cells were routinely kept as monolayer cultures at 37° C. in ahumidified 5% CO₂ atmosphere. Cells were passaged once a week using atrypsin/EDTA solution at a split ratio of 1:40. All media andsupplements were obtained from Life Technologies. Cells were free ofmycoplasma contamination as determined using the Gen-Probe MycoplasmaTissue Culture kit (supplier: BioMérieux).

Cells were seeded in NUNC™ 96-well culture plates (Supplier: LifeTechnologies) and allowed to adhere to the plastic overnight. Densitiesused for plating were 1500 cells per well in a total volume of 200 μlmedium. After cell adhesion to the plates, medium was changed and drugsand/or solvents were added to a final volume of 200 μl. Following fourdays of incubation, medium was replaced by 200 μl fresh medium and celldensity and viability was assessed using an MTT-based assay. To eachwell, 25 μl INTM solution was added and the cells were further incubatedfor 2 hours at 37° C. The medium was then carefully aspirated and theblue MTT-formazan product was solubilized by addition of 25 μl glycinebuffer followed by 100 μl of DMSO. The microtest plates were shaken for10 min on a microplate shaker and the absorbance at 540 nm was measuredusing an Emax 96-well spectrophotometer (Supplier: Sopachem). Within anexperiment, the results for each experimental condition are the mean of3 replicate wells. For initial screening purposes, compounds were testedat a single fixed concentration of 10⁻⁶ M. For active compounds, theexperiments were repeated to establish full concentration-responsecurves. For each experiment, controls (containing no drug) and a blankincubation (containing no cells or drugs) were run in parallel. Theblank value was subtracted from all control and sample values. For eachsample, the mean value for cell growth (in absorbance units) wasexpressed as a percentage of the mean value for cell growth of thecontrol. When appropriate, IC₅₀-values (concentration of the drug,needed to reduce cell growth to 50% of the control) were computed usingprobit analysis for graded data (Finney, D. J., Probit Analyses, 2^(nd)Ed. Chapter 10, Graded Responses, Cambridge University Press, Cambridge1962). Herein the effects of test compounds are expressed as pIC₅₀ (thenegative log value of the IC₅₀-value)(see Table F-3).

EXAMPLE C.3 Solubility/Stability

C.3 a. Kinetic Solubility in Aqueous Media

In the first dilution step, 10 μl of a concentrated stock-solution ofthe active compound, solubilized in DMSO (5 mM), was added to 100 μlphosphate citrate buffer pH 7.4 and mixed. In the second dilution step,an aliquot (20 μl) of the first dilution step was further dispensed in100 μl phosphate citrate buffer pH 7.4 and mixed. Finally, in the thirddilution step, a sample (20 μl) of the second dilution step was furtherdiluted in 100 μl phosphate citrate buffer pH 7.4 and mixed. Alldilutions were performed in 96-well plates. Immediately after the lastdilution step the turbidity of the three consecutive dilution steps weremeasured with a nephelometer. Dilution was done in triplicate for eachcompound to exclude occasional errors. Based on the turbiditymeasurements a ranking is performed into 3 classes. Compounds with highsolubility obtained a score of 3 and for this compounds the firstdilution is clear. Compounds with medium solubility obtained a score of2. For these compounds the first dilution is unclear and the seconddilution is clear. Compounds with low solubility obtained a score of 1and for these compounds both the first and the second dilution areunclear (see Table F-3).

C.3.b. Solubility

The solubility of a compound, at different pH's, can also be measuredwith the use of a cherniluminescent nitrogen detector (see Table F-3).

EXAMPLE C.4 Parallel Artificial Membrane Permeability Analysis

The stock samples (aliquots of 10 μl of a stock solution of 5 mM in 100%DMSO) were diluted in a deep-well or Pre-mix plate containing 2 ml of anaqueous buffer system pH 4 or pH 7.4 (PSR4 System Solution Concentrate(pION)). Before samples were added to the reference plate, 150 μl ofbuffer was added to wells and a blank UV-measurement was performed.Thereafter the buffer was discarded and the plate was used as referenceplate. All measurements were done in UV-resistant plates (supplier:Costar or Greiner).

After the blank measurement of the reference plate, 150 μl of thediluted samples was added to the reference plate and 200 μl of thediluted samples was added to donorplate 1. An acceptor filter plate 1(supplier: Millipore, type:MAIP N45) was coated with 4 μl of theartificial membrane-forming solution(1,2-Dioleoyl-sn-Glycer-3-Phosphocholine in Dodecane containing 0.1%2,6-Di-tert-butyl-4-methylphenol and placed on top of donor plate 1 toform a “sandwich”. Buffer (200 μl) was dispensed into the acceptor wellson the top. The sandwich was covered with a lid and stored for 18 h atroom temperature in the dark.

A blank measurement of acceptor plate 2 was performed through theaddition of 150 μl of buffer to the wells, followed by anUV-measurement. After the blank measurement of acceptor plate 2 thebuffer was discarded and 150 μl of acceptor solution was transferredfrom the acceptor filter plate 1 to the acceptor plate 2. Then theacceptor filter plate 1 was removed form the sandwich. After the blankmeasurement of donor plate 2 (see above), 150 μl of the donor solutionwas transferred from donor plate 1 to donor plate 2. The UV spectra ofthe donor plate 2, acceptor plate 2 and reference plate wells werescanned (with a SpectraMAX 190). All the spectra were processed tocalculate permeability with the PSR4p Command Software. All compoundswere measured in triplo. Carbamazepine, griseofulvin, acycloguanisine,atenolol, furosemide, and chlorothiazide were used as standards in eachexperiment. Compounds were ranked in 3 categories as having a lowpermeability (mean effect <0.5×10⁻⁶ cm/s; score 1), a mediumpermeability (1×10⁻⁶ cm/s>mean effect≧0.5×10⁻⁶ cm/s; score 2) or a highpermeability (≧1×10⁻⁶ cm/s; score 3).

EXAMPLE C.5 Metabolic Stability EXAMPLE C.5.a.

Sub-cellular tissue preparations were made according to Gorrod et al.(Xenobiotica 5: 453-462, 1975) by centrifugal separation aftermechanical homogenization of tissue. Liver tissue was rinsed in ice-cold0.1 M Tris-HCI (pH 7.4) buffer to wash excess blood. Tissue was thenblotted dry, weighed and chopped coarsely using surgical scissors. Thetissue pieces were homogenized in 3 volumes of ice-cold 0.1 M phosphatebuffer (pH 7.4) using either a Potter-S (Braun, Italy) equipped with aTeflon pestle or a Sorvall Omni-Mix homogeniser, for 7×10 sec. In bothcases, the vessel was kept in/on ice during the homogenization process.

Tissue homogenates were centrifuged at 9000×g for 20 minutes at 4° C.using a Sorvall centrifuge or Beckman Ultracentrifuge. The resultingsupernatant was stored at −80 ° C. and is designated ‘S9’.

The S9 fraction can be further centrifuged at 100.000×g for 60 minutes(4° C.) using a Beckman ultracentrifuge. The resulting supernatant wascarefully aspirated, aliquoted and designated ‘cytosol’. The pellet wasre-suspended in 0.1 M phosphate buffer (pH 7.4) in a final volume of 1ml per 0.5 g original tissue weight and designated ‘microsomes’.

All sub-cellular fractions were aliquoted, immediately frozen in liquidnitrogen and stored at −80 ° C. until use.

For the samples to be tested, the incubation mixture contained PBS(0.1M), compound (5 μM), microsomes (1 mg/ml) and a NADPH-generatingsystem (0.8 mM glucose-6-phosphate, 0.8 mM magnesium chloride and 0.8Units of glucose-6-phosphate dehydrogenase). Control samples containedthe same material but the microsomes were replaced by heat inactivated(10 min at 95 degrees Celsius) microsomes. Recovery of the compounds inthe control samples was always 100%.

The mixtures were preincubated for 5 min at 37 degrees Celsius. Thereaction was started at timepoint zero (t=0) by addition of 0.8 mM NADPand the samples were incubated for 15 min (t=15). The reaction wasterminated by the addition of 2 volumes of DMSO. Then the samples werecentrifuged for 10 min at 900×g and the supernatants were stored at roomtemperature for no longer as 24 h before analysis. All incubations wereperformed in duplo. Analysis of the supernatants was performed withLC-MS analysis. Elution of the samples was performed on a Xterra MS C18(50×4.6 mm, 5 μm, Waters, US). An Alliance 2790 (Supplier: Waters, US)HPLC system was used. Elution was with buffer A (25 mM ammoniumacetate(pH 5.2) in H₂O/acetonitrile (95/5)), solvent B being acetonitrile andsolvent C methanol at a flow rate of 2.4 ml/min. The gradient employedwas increasing the organic phase concentration from 0% over 50% B and50% C in 5 min up to 100% B in 1 min in a linear fashion and organicphase concentration was kept stationary for an additional 1.5 min. Totalinjection volume of the samples was 25 μl.

A Quattro (supplier: Micromass, Manchester, UK) triple quadrupole massspectrometer fitted with and ESI source was used as detector. The sourceand the desolvation temperature were set at 120 and 350° C. respectivelyand nitrogen was used as nebuliser and drying gas. Data were acquired inpositive scan mode (single ion reaction). Cone voltage was set at 10 Vand the dwell time was 1 sec.

Metabolic stability was expressed as % metabolism of the compound after15 min of incubation in the presence of active microsomes (E(act)) (%metabolism=100% −

$\left( {\left( \frac{{{Total}\mspace{14mu}{ION}\mspace{14mu}{Current}\mspace{14mu}({TIC})\mspace{14mu}{of}\mspace{14mu}{E({act})}\mspace{14mu}{at}\mspace{14mu} t} = 15}{{{TIC}\mspace{14mu}{of}\mspace{14mu}{E({act})}\mspace{14mu}{at}\mspace{14mu} t} = 0} \right) \times 100} \right).$Compounds that had a percentage metabolism less than 20% were defined ashighly metabolic stable. Compound that had a metabolism between 20 and70% were defined as intermediately stable and compounds that showed apercentage metabolism higher than 70 were defined as low metabolicstable. Three reference compounds were always included whenever ametabolic stability screening was performed. Verapamil was included as acompound with low metabolic stability (% metabolism=73%). Cisapride wasincluded as a compound with medium metabolic stability (% metabolism45%) and propanol was included as a compound with intermediate to highmetabolic stability (25% metabolism). These reference compounds wereused to validate the metabolic stability assay.C.5.b: Metabolic Stability with Rat Hepatocytes Cell Culture

Rat hepatocytes were isolated from male Sprague Dowley rats. Thecompounds were dissolved to a 5 mM stock solution in 100% DMSO andincubated at a final concentration of 5 μM for 0, 15, 30, 60 and 120 minwith rat hepatocyte cell cultures (0.5 million viable cells/0.5 ml)using 24-well plates.

Samples were prepared for LC-MS by addition of two volumes of DMSO. Thesamples were thoroughly shaken and subsequently centrifuged at 900 g for10 min (room temperature). All experiments were performed in triplicate.Of the resulting supernatant 50 μl was analysed by LC-MS.

For LC-MS, elution of samples was performed on a Hypersil BDS C18 column(50×4.6 mm, 5 μm, Thermohypersil, UK). The HPLC system comprised aSurveyor delivery system (Surveyor Inc., San Jose, US) equipped with aSurveyor autosampler device. Elution was with buffer A (10 mMammoniumacetate (pH 6.9) in H₂O/Acetonitrile (95:5)) and solvent B(acetonitrile) at a flow rate of 1.2 ml/min. The gradient employed was0.5 min solvent A as start condition followed by increasing the organicphase concentration from 0% B till 95% B over 2 min in a linear fashion.This phase was kept stationary for a further 2 min and reduced again to0% B within 0.5 min.

Total injection volume of samples was 50 μL. Column oven temperature waskept at 40° C. The LC flow was splitted for MS detection and 0.1 ml letinto the source. An triple quadrupol mass spectrometer TSQ Quantum(Thermofinnigan, LaJolla, USA) mass spectrometer fitted with an ESIsource was used for detection. Source voltage was set at 3800 volt, thecapillary temperature at 300° C. The mass spectrometer was operated inpositive ion mode in SIM adjusted to the mass of M+H with a scan widthof 1 Da for quantification purposes. Instrument control, dataacquisition and processing were performed using the Xcalibur software(ThermoFinnigan, San Jose, Calif., U.S.A). The metabolic stability ofcompounds in rat hepatocytes was expressed as in vitro half-lives.

As reference, compound R306465 (WO03/76422) was used (in vitrohalf-live: 8 min). Compound 4 of the present application was tested andhad an in vitro half-live of 23 min.

EXAMPLE C.6 p21 Induction Capacity EXAMPLE C.6.a p21 Enzyme LinkedImmunosorbent Assay

The following protocol has been applied to determine the p21 proteinexpression level in human A2780 ovarian carcinoma cells. The A2780 cells(20000 cells/180 μl) were seeded in 96 microwell plates in RPMI 1640medium supplemented with 2 mM L-glutamine, 50 μg/ml gentamicin and 10%fetal calf serum. 24 hours before the lysis of the cells, compounds wereadded at final concentrations of 10⁻⁵, 10^(−6, 10) ⁻⁷ and 10⁻⁸ M. Allcompounds tested were dissolved in DMSO and further dilutions were madein culture medium. 24 hours after the addition of the compound, thesupernatants were removed from the cells. Cells were washed with 200 μlice-cold PBS. The wells were aspirated and 30 μl of lysisbuffer (50 mMTris.HCl (pH 7.6), 150 mM NaCl, 1% Nonidet p40 and 10% glycerol) wasadded. The plates were incubated overnight at −70° C.

The appropriate number of microtiter wells were removed from the foilpouch and placed into an empty well holder. A working solution (1×) ofthe Wash Buffer (20× plate wash concentrate: 100 ml 20-fold concentratedsolution of PBS and surfactant. Contains 2% chloroacetamide) wasprepared. The lyophilised p21WAF standard was reconstituted withdistilled H₂O and further diluted with sample diluent (provided in thekit)

The samples were prepared by diluting them 1:4 in sample diluent. Thesamples (100 μl) and the p21WAF1 standards (100 μl) were pipetted intothe appropriate wells and incubated at room temperature for 2 hours. Thewells were washed 3 times with 1× wash buffer and then 100 μl ofdetector antibody reagent (a solution of biotinylated monoclonal p21WAF1antibody) was pipetted into each well. The wells were incubated at roomtemperature for 1 hour and then washed three times with 1× wash buffer.The 400× conjugate (peroxidase streptavidine conjugate: 400-foldconcentrated solution) was diluted and 100 μl of the 1× solution wasadded to the wells. The wells were incubated at room temperature for 30min and then washed 3 times with 1× wash buffer and 1 time withdistilled H₂O. Substrate solution (chromogenic substrate)(100 μl) wasadded to the wells and the wells were incubated for 30 minutes in thedark at room temperature. Stop solution was added to each well in thesame order as the previously added substrate solution. The absorbance ineach well was measured using a spectrophotometric plate reader at dualwavelengths of 450/595 nm.

For each experiment, controls (containing no drug) and a blankincubation (containing no cells or drugs) were run in parallel. Theblank value was substracted from all control and sample values. For eachsample, the value for p21WAF1 induction (in absorbance units) wasexpressed as the percentage of the value for p21WAF1 present in thecontrol. Percentage induction higher than 130% was defined assignificant induction. Four compounds were tested and all showedsignificant induction.

EXAMPLE C.6.b. CEllular Method

A2780 cells (ATCC) were cultivated in RPMI 1640 medium supplemented with10% FCS, 2 mM L-glutamine and gentamycine at 37° C. in a humidifiedincubator with 5% CO₂. All cell culture solutions are provided byGibco-BRL (Gaithersburg, Md.). Other materials are provided by Nunc.

Genomic DNA was extracted from proliferating A2780 cells and used astemplate for nested PCR isolation of the p21 promoter. The firstamplification was performed for 20 cycles at an annealing temperature of55° C. using the oligonucleotide pair GAGGGCGCGGTGCTTGG andTGCCGCCGCTCTCTCACC with the genomic DNA as template. The resulting 4.5kb fragment containing the −4551 to +88 fragment relative to the TATAbox was re-amplified with the oligonucleotidesTCGGGTACCGAGGGCGCGGTGCTTGG and ATACTCGAGTGCCGCCGCTCTCTCACC for 20 cycleswith annealing at 88° C. resulting in a 4.5 kb fragment and subsequentlywith the oligonucleotide pair TCGGGTACCGGTAGATGGGAGCGGATAGACACATC andATACTCGAGTGCCGCCGCTCTCTCACC for 20 cycles with annealing at 88° C.resulting in a 1.3 kb fragment containing the −1300 to +88 fragmentrelative to the TATA box. The restriction sites XhoI and KpnI present inthe oligonucleotides (underlined sequence) were used for subcloning.

The luciferase reporter was removed from the pGL3-basic and replaced bythe ZsGreen reporter (from the pZsGreen1-N1 plasmid) at KpnI and XbaIrestriction sites. pGL3-basic-ZsGreen-1300 was constructed via insertionof the above mentioned 1.3 kb fragment of the human p21 promoter regioninto pGL3-basic-ZsGreen at the XhoI and KpnI sites. All restrictionenzymes are provided by Boehringer Manheim (Germany). A2780 cells wereplated into a 6-well plate at a density of 2×10⁵ cells, incubated for 24hours, and transfected with 2 μg of pGL3-basic-ZsGreen-1300 and 0.2 μgof pSV2neo vector by using Lipofectamine 2000 (Invitrogen, Brussels,Belgium) as described by manufacturer. The transfected cells wereselected for 10 days with G418 (Gibco-BRL, Gaithersburg, Md.) and singlecell suspensions were grown. After three weeks, single clones wereobtained.

The A2780 selected clones were expanded and seeded at 10000 cells perwell into 96-well plates. 24 hours after seeding, the cells were treatedfor an additional 24 hours with compounds (affecting sp1 sites in theproximal p21 promoter region). Subsequently, cells were fixed with 4%PFA for 30′ and counterstained with Hoechst dye. The p21 promoteractivation leading to ZsGreen production and thus fluorescence, wasmonitored by the Ascent Fluoroskan (Thermo Labsystems, Brussels,Belgium).

For each experiment, controls (containing no drug) and a blankincubation (containing no cells or drugs) were run in parallel. Theblank value was substracted from all control and sample values. For eachsample, the value for p21 induction was expressed as the percentage ofthe value for p21 present in the control. Percentage induction higherthan 130% was defined as significant induction.

Twenty-six compounds were tested and showed significant induction.

EXAMPLE C.6.c. in vivo Method

A selected clone was injected subcutaneous (10⁷ cells/200 μl) into theflank of nude mice and a calliper measurable tumour was obtained after12 days. From day 12 on, animals were dosed, orally or intraveinally,daily during 6 days with solvent and 20-40 mpk compound (4-10 animalseach). Tumours were evaluated for fluorescence by the in-house developedAutomated Whole Body Imaging System (Fluorescent stereomicroscope typeOlympus® SZX12 equipped with a GFP filter and coupled to a CCD cameratype JAI® CV-M90 controlled by a software package based on the IMAQVision Software from National Instruments®). As reference, compoundR306465 (WO03/76422) was used. Compounds were ranked as inactive (nofluorescence measurable), weaker, identical or better than R306465.Compound 1 was tested and was better than R306465 after oraladministration.

EXAMPLE C.7 P450 Inhibiting Capacity

All compounds tested were dissolved in DMSO (5 mM) and a furtherdilution to 5 10⁻⁴ M was made in acetonitrile. Further dilutions weremade in assay buffer (0.1M NaK phosphate buffer pH 7.4) and the finalsolvent concentration was never higher than 2%.

The assay for the CYP3A4 protein comprises per well 15 pmol P450/mgprotein (in 0.01M NaKphosphate buffer+1.15% KCl), an NADPH generatingsystem (3.3 mM Glucose-6-phosphate, 0.4 U/ml Glucose-6-phosphatedehydrogenase, 1.3 mM NADP and 3.3 mM MgCl₂.6H₂O in assay buffer) andcompound in a total assay volume of 100 μl. After a 5 min pre-incubationat 37° C. the enzymatic reaction was started with the addition of 150 μMof the fluoresent probe substrate BFC in assay buffer. After anincubation of 30 minutes at room temperature the reaction was terminatedafter addition of 2 volumes of acetonitrile. Fluorescent determinationswere carried out at an excitation wavelength of 405 nm and an emissionwavelength of 535 nm. Ketoconazole (IC₅₀-value=3×10⁻⁸M) was included asreference compound in this experiment. The assay for the CYP2D6 proteincomprises per well 6 pmol P450/mg protein (in 0.01M NaKphosphatebuffer+1.15% KCl), an NADPH generating system (0.41 mMGlucose-6-phosphate, 0.4 U/ml Glucose-6-phosphate dehydrogenase, 0.0082mM NADP and 0.41 mM MgCl₂.6H₂O in assay buffer) and compound in a totalassay volume of 100 μl. After a 5 min pre-incubation at 37° C. theenzymatic reaction was started with the addition of 3 μM of thefluoresent probe substrate AMMC in assay buffer. After an incubation of45 minutes at room temperature the reaction was terminated afteraddition of 2 volumes of acetonitrile. Fluorescent determinations werecarried out at an excitation wavelength of 405 nm and an emissionwavelength of 460 nm. Quinidine (IC₅₀-value<5×10⁻⁸M) was included asreference compound in this experiment.

The assay for the CYP2C9 protein comprises per well 15 pmol P450/mgprotein (in 0.01M NaKphosphate buffer+1.15% KCl), an NADPH generatingsystem (3.3 mM Glucose-6-phosphate, 0.4 U/ml Glucose-6-phosphatedehydrogenase, 1.3 mM NADP and 3.3 mM MgCl₂.6H₂O in assay buffer) andcompound in a total assay volume of 100 μl. After a 5 min pre-incubationat 37° C. the enzymatic reaction was started with the addition of 200 μMof the fluoresent probe substrate MFC in assay buffer. After anincubation of 30 minutes at room temperature the reaction was terminatedafter addition of 2 volumes of acetonitrile. Fluorescent determinationswere carried out at an excitation wavelength of 405 nm and an emissionwavelength of 535 nm. Sulfaphenazole (IC₅₀-value=6.8×10⁻⁷M) was includedas reference compound in this experiment.

For initial screening purposes, compounds were tested at a single fixedconcentration of 1×10⁻⁵ M. For active compounds, the experiments wererepeated to establish full concentration-response curves. For eachexperiment, controls (containing no drug) and a blank incubation(containing no enzyme or drugs) were run in parallel. All compounds wereassayed in quadruplicate. The blank value was subtracted from allcontrol and sample values. For each sample, the mean value of P450activity of the sample (in relative fluorescence units) was expressed asa percentage of the mean value of P450 activity of the control.Percentage inhibition was expressed as 100% minus the mean value of P450activity of the sample. When appropriate, IC₅₀-values (concentration ofthe drug, needed to reduce P450 activity to 50% of the control) werecalculated.

TABLE F-3 lists the results of the compounds that were tested accordingto example C.1, C.2, C.3.a. and C.3.b Enzymatic Cellular activityactivity Solubility Compound pIC50 pIC50 C.3.b. number C.1. C.2. pH =2.3 mg/ml Solubility C.3.a. 1 8.2 7.9 3 2 7.4 6.5 3 3 8.1 7.5 3 4 8.27.5 3 5 7.9 7.4 1 6 7.6 7.4 3 7 >9 7.5 2.0 8 8.8 7.9 2.9 9 9.4 7.6 108.4 7.5 3.0 11 9.4 8.0 3.1 12 9.0 7.5 2.1 13 8.8 7.0 3.7 14 8.5 7.4 2.815 7.6 7.0 3 16 7.4 7.1 2.8 17 8.8 6.7 2.2 18 8.5 7.0 3.6 19 8.4 6.3 2.620 7.7 7.3 21 7.9 6.8 2.1 22 7.9 6.8 4.2 23 8.0 6.6 24 8.8 7.5 4.0 257.9 7.6 3.4 26 8.3 7.2 3.5 27 >9 7.5 28 >9 7.5 31 8.5 7.4 32 >9 >7.533 >9 8.2 34 8.8 7.9 35 9.6 7.8D. Composition Example: Film-coated TabletsPreparation of Tablet Core

A mixture of 100 g of formula (I), 570 g lactose and 200 g starch ismixed with and thereafter humidified with a solution of 5 g sodiumdodecyl sulphate and 10 g polyvinyl-pyrrolidone in about 200 ml ofwater. The wet powder mixture is sieved, dried and sieved again, Thenthere is added 100 g microcrystalline cellulose and 15 g hydrogenatedvegetable oil. The whole is mixed well and compressed into tablets,giving 10.000 tablets, each comprising 10 mg of a compound of formula(I).

Coating

To a solution of 10 g methyl cellulose in 75 ml of denaturated ethanolthere is added a solution of 5 g of ethyl cellulose in 150 ml ofdichloromethane. Then there are added 75 ml if ducgkirinetgabe and 2.5ml 1,2,3-propanetriol 10 g of polyethylene glycol is molten anddissolved in 75 ml of dichloromethane. The latter solution is added tothe former and then there are added 2.5 g of magnesium octadecanoate, 5g of polyvinyl-pyrrolidone and 30 ml of concentrated colour suspensionand the whole is homogenated. The tablet cores are coated with the thusobtained mixture in a coating apparatus.

1. A compound of formula (I),

or a pharmaceutically acceptable addition salt or a stereo-chemicallyisomeric form thereof, wherein R¹ is phenyl; wherein said phenyl isoptionally substituted with one or two substituents each independentlyselected from halo, C₁₋₆alkyl, C₁₋₆alkyloxy, polyhaloC₁₋₆alkyl, andphenyl; R² is hydrogen, —CH₂—R⁵, trifluoromethyl, —C(═O)—R⁶, or—CH₂—NR⁷R⁸; wherein each R⁵ is independently selected from hydrogen,hydroxy, C₁₋₆alkyloxy, C₁₋₆alkyloxyC₁₋₆alkyloxy, C₁₋₆alkylcarbonyloxy,piperazinyl, N-methylpiperazinyl, morpholinyl, thiomorpholinyl,imidazolyl or triazolyl; each R⁶ is independently selected from hydroxy,C₁₋₆alkyloxy, amino or mono- or di(C₁₋₆alkyl)amino, C₁₋₆cycloalkylamino,hydroxyC₁₋₆alkylamino, piperazinyl, mono- ordi(C₁₋₆alkyl)aminoC₁₋₆alkylamino N-methylpiperazinyl, morpholinyl orthiomorpholinyl; each R⁷ and R⁸ are independently selected fromhydrogen, C₁₋₆alkyl, C₁₋₆alkylcarbonyl, C₁₋₆alkylsulfonyl, or mono-ordi(C₁₋₄alkyl)aminosulfonyl; R³ is hydrogen, hydroxymethyl, aminomethylor mono- or di(C₁₋₆alkyl)aminomethyl; and R⁴ is hydrogen or C₁₋₆alkyl.2. A compound according to claim 1 wherein R¹ is phenyl or phenyloptionally substituted with halo, C₁₋₆alkyl, C₁₋₆alkyloxy,polyhaloC₁₋₆alkyl or phenyl; R² is —CH₂—R⁵ or —C(═O)—R⁶; each R⁵ isindependently selected from hydrogen, hydroxy, C₁₋₆alkyloxy,C₁₋₆alkyloxyC₁₋₆alkyloxy, C₁₋₆alkylcarbonyloxy, N-methylpiperazinyl,morpholinyl or imidazolyl; each R⁶ is independently selected fromC₁₋₆alkylamino, C₁₋₆cycloalkylamino, hydroxyC₁₋₆alkylamino,di(C₁₋₆alkyl)aminoC₁₋₆alkylamino or morpholinyl; R³ is hydrogen and R⁴is hydrogen or C₁₋₆alkyl.
 3. A compound according to claim 1 wherein R¹is phenyl or phenyl substituted with halo; R² is —CH₂—R⁵; each R⁵ isindependently selected from hydrogen, hydroxy, C₁₋₆alkyloxy, orC₁₋₆alkylcarbonyloxy; R³ is hydrogen; and R⁴ is hydrogen.
 4. A compoundselected from the group consisting of:


5. A pharmaceutical composition comprising one or more pharmaceuticallyacceptable carriers and as an active ingredient a therapeuticallyeffective amount of a compound as claimed in claim
 1. 6. Apharmaceutical composition comprising one or more pharmaceuticallyacceptable carriers and as an active ingredient a therapeuticallyeffective amount of a compound as claimed in claim
 2. 7. Apharmaceutical composition comprising one or more pharmaceuticallyacceptable carriers and as an active ingredient a therapeuticallyeffective amount of a compound as claimed in claim
 3. 8. Apharmaceutical composition comprising one or more pharmaceuticallyacceptable carriers and as an active ingredient a therapeuticallyeffective amount of a compound as claimed in claim 4.